

## **UTILITY PATENT APPLICATION TRANSMITTAL** (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. Army 111₺

Total Pages in this Submission

## TO THE ASSISTANT COMMISSIONER FOR PATENTS

**Box Patent Application** Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.	C. 111(a) and 37 C.F.R.	1.53(b) is a new utility	patent application for an
invention entitled:			

inv <u>enti</u>	ion e	ntitle	d:						(b) is a new utility patent ap	
ON	VEL	" <b>BU</b> ]	RST-I	FRE	E" SUSTAIN	ED R	ELEASE POLY	/-(LACTIDE/G	ELYCOLIDE) MICROPHEI	SES 1945 1945 1945 1945 1945 1945 1945 1945
and in		<u>.</u>								33.5
Jeya	anthi,	, et al	•							jc549 09/
If a C	ONT	INUA	TION	I AP	PLICATION,	ched	ck appropriate b	oox and supply	the requisite information:	
⊠ C	Conti	nuat	ion		Divisional		Continuation	-in-part (CIP)	of prior application No.: _	08/590,973
Which  Which	Conti	nuat	ion		Divisional	×	Continuation	-in-part (CIP)	of prior application No.: _	08/446,149
	Conti		ion		Divisional		Continuation	-in-part (CIP)	of prior application No.: _	
‡ncio: ∐	sea a	are:					Applicatio	n Elements		
<u>.</u> 1.	Application Elements  The state of the state									
2.	X	Spe	cifica	tion	having		41	_ pages and ir	ncluding the following:	
	a. 🗵 Descriptive Title of the Invention									
	b. 🗵 Cross References to Related Applications (if applicable)									
	C.	X	Statement Regarding Federally-sponsored Research/Development (if applicable)							
	d.		Reference to Microfiche Appendix (if applicable)							
	e. 🗵 Background of the Invention									
	f.	X	Brief Summary of the Invention							
	g.	X	Brief Description of the Drawings (if drawings filed)							
	h.	X	Detailed Description							
	i.	X	Clair	n(s)	as Classified	Belo	)W			
	j.	X	Abst	ract	of the Disclos	sure				

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
Army 111

Total Pages in this Submission

	3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)										
		a.		Formal		Number of Sheets							
		b.	X	Informal		Number of Sheets		8					
	4.		☐ Oath or Declaration										
		a.		Newly execu	ted (o	riginal or copy)	☐ Un	executed					
		b.	b. 🗵 Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)										
		c.	X	With Power of									
Harly Carl		d.		DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).									
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).  5. ☑ Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declarate under Box 4b, is considered as being part of the disclosure of the accompanying application incorporated by reference therein.  6. ☐ Computer Program in Microfiche (Appendix)													
7.   Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)									ded)				
Hard that their their		a.		Paper Copy									
"" H""		b.		Computer Re	eadab	e Copy (identical to	compute	r copy)					
c.   Statement Verifying Identical Paper and Computer Readable Copy													
		Accompanying Application Parts											
	8.	X	Assignment Papers (cover sheet & document(s))										
	9.		37 CFR 3.73(B) Statement (when there is an assignee)										
	10.		English Translation Document (if applicable)										
	11.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations										
	12.	X	Preliminary Amendment										
	13.	×	Acknowledgment postcard										
	14.	X	Certificate of Mailing										
				First Class	X	Express Mail <i>(Spec</i>	ify Label I	No.): EJ696	6804272US				

**Application Elements (Continued)** 

## UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
Army 111

Total Pages in this Submission

Accompanying Application Parts (Continued)												
15.   Certified Copy of Priority Document(s) (if foreign priority is claimed)												
16. 🗌 Additiona	.   Additional Enclosures (please identify below):											
19 April 19		Fee Calculat	ion and Tra	nsmitta	ıl							
200		CLAIMS A	S FILED									
For	#Filed	#Allowed	#Extra		Rate		Fee					
otal Claims	46	- 20 =	26	x	\$18.00		\$468.00					
idep. Claims	dep. Claims 4 - 3 = 1 × \$78.00 \$78.04											
ultiple Dependent	Claims (check i	f applicable)	]				\$0.00					
A STATE OF THE STA						BASIC FEE	\$760.00					
OTHER FEE (specif	fy purpose)											
					TOTAL	FILING FEE	\$1,306.00					
A check in the amount of to cover the filing fee is enclosed.  In Commissioner is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. A duplicate copy of this sheet is enclosed.  In Charge the amount of \$1,306.00 as filing fee.  In Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.  In Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).												
Pated: June 22, 1999 ec:	)		Re Na 34 Br	15 Brook	6, 329 tus, LLD keville Rd. , e, Maryland							

CERTIFICATE OF I Applicant(s): Jeyanthi, e Serial No. Cont. of 08/590,973		Docket No.  Army 111A  Group Art Unit  1617		
Invention: NOVEL "BU	IRST-FREE" SUSTAINED RELI	EASE POLY-(LACTIDE/GLY	COLI	DE) MICROSPHERES
	h the United States Postal Servinvelope addressed to: The Com  June 22, 1999	(Identify type of correspondence) ce "Express Mail Post Office	to Add	dressee" service under
37 CFR 1.10 in an er 20231-0001 on	(Date)	Caroline (Typed or Printed Name of Person (Signature of Person Mailin EJ6968042 ("Express Mail" Mailing	Mailing  Mac  Mac  Mac  Mac  Mac  Mac  Mac  Ma	spondence)
	Note: Each paper must ha	eve its own certificate of mailing.		

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of JEYANTHI et al.
Rule 53(b) Continuation appl. Of Appln. No.: 08/590,973

Filed: January 24, 1996

Examiner: Harrison, R.H.

Group Art Unit: 1617

FOR: NOVEL "BURST-FREE" SUSTAINED RELEASE POLY-(LACTIDE/GLYCOLIDE) MICROSPHERES

\* \* \* \* \*

June 22, 1999

### PRELIMINARY AMENDMENT

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In connection with the above-referenced continuation application filed concurrently herewith, please enter the following amendments before examination on the merits.

## **IN THE SPECIFICATION:**

Page 1, line 14, after "is" insert --- a continuation application of U.S. Patent Application Serial No. 08/590,973, filed January 24, 1996, which is --.

Page 6, line 20, delete "12k" second occurrence.

Page 8, line 19, replace "coploymer" with -copolymer--.

Page 12, line 16, after "13" insert —wherein the biologically active agent is a polypeptide--;

line 23, delete "of" first occurrence;

line 25, replace "microshreres" with --microspheres--.

```
Page 18, line 3, replace "precipitous" with -precipitous--;
         line 7, replace "yor" with -or--;
         line 13, after "other' insert -biologically active agents from--.
Page 27, line 5, replace "microshperes" with -microspheres--;
         line 22, after "1-12", replace "week" with -week--.
Page 28, line 14, replace "actice" with –active--;
         line 20, replace "rations" with -ratios--;
         line 50, replace "1a and 1b" with --2 and 4--.
Page 29, line 32, replace "2" with --5--;
         line 49, replace "2" with --5--.
Page 30, line 13, replace "3" with--5--;
         line 28, replace "2" with --3--;
         line 43, replace "3" with ---5--.
Page 31, line 6, replace "3" with ---5--;
         line 22, replace "2" with ---3--;
          line 33, replace "is" with –are--;
          line 34, replace "; and is" with --. They are--;
          line 35, replace "4" with ---7--.
Page 32, line 20, replace "2 and 3" with --3 and 5--;
```

line 24, replace "these figures" with -- Figure 6--.

## **IN THE CLAIMS:**

Please amend the claims as follows:

- 1. (Amended) A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a biologically active agent over a duration from 1-100 days, comprising an active agent and [a blend of] uncapped and end-capped biodegradable poly(lactide/glycolide) polymers.
- 2. (Amended) The microcapsule pharmaceutical formulation of claim 1, wherein [the biodegradable poly (lactide/glycolide) is a blend of] a copolymer ratio of uncapped and end-capped forms of biodegradable poly (lactide/glycolide) polymers [capped forms, in ratios ranging from] is 100/0 to 1/99.
- 3. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2] claim 2 wherein the copolymer (lactide to glycolide L/G) ratio for uncapped and [endcapped] end-capped polymer is 52/48 to 48/52.
- 4. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2] claim 2 wherein the copolymer (lactide to glycolide L/G) ratio for uncapped and end-capped polymer is 90/10 to 40/60.
- 5. (Amended) The [microcapsules] <u>microcapsule pharmaceutical formulation</u> of claim 3 wherein the molecular weight of the copolymer is between 2,000-60,000 daltons.
- 6. (Amended) The [microcapsules] <u>microcapsule pharmaceutical formulation</u> of claim 1 wherein the biologically active agent is a peptide or polypeptide.

- 7. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6, wherein said polypeptide is histatin [consisting of 12 amino acids and having a molecular weight of 1563].
- 8. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 7 [characterized by the] having a capacity to completely release the histatin in an aqueous physiological environment from 1-35 days with a 100/0 [blend] ratio of uncapped and end-capped poly(lactide/glycolide) having an L/G ratio of 48/52 to 52/48, and a molecular weight <15,000 daltons.
- 9. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 7 [characterized by the] having a capacity to completely release the histatin in an aqueous physiological environment from 18-40 days with a 100/0 [blend] ratio of uncapped and end-capped poly(lactide/glycolide) having an L/G ratio of 48/52 to 52/48 and a molecular weight range of 28,000-40,000 daltons.
- 10. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 7 [characterized by the] having a capacity to release up to 90% of the histatin in an aqueous physiological environment from 28-70 days with a 0/100 [blend] ratio of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 10,000 40,000 daltons.
- 11. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 7 [characterized by the] having a capacity to release up to 80% of the histatin in an aqueous physiological environment from 56-100 days with a 0/100 [blend] ratio of

uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 75/25 and a molecular weight of <15,000 daltons.

- 12. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 7 or 8 or 9 or 10 or 11] claim 7 having analogs of histatin with chain lengths of from 11-24 amino acids of molecular weights from 1,500-3,000 daltons and characterized by the following structures:
  - 1. DSHAKRHHGYKRKFHEKHHSHRGY
  - 2. KRHHGYKRKFHEKHHSHRGYR
  - 3. KRHHGYKRKFHEKHHSHR
  - 4. RKFHEKHHSHRGYR
  - 5. AKRHHGYKRKFH
  - 6. \*AKRHHGYKRKFH
  - 7. KRHHGYKRKF

13. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6 wherein the biologically active agent is a polypeptide Leutinizing hormone releasing hormone (LHRH) that is decapeptide of molecular weight 1182 in its acetate form, and having the structure:

### p-EHWSYGLRPG.

14. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6 comprising a polypeptide, wherein said polypeptide has [having] a molecular weight of from 1,000 to 250,000 daltons.

<sup>\*</sup>d-amino acid.

- 15. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14] claim 1 wherein [release profiles of variable] varying release rates and varying release durations of the active agent are achieved by blending uncapped and [capped microspheres] end-capped polymers as a cocktail in variable amounts.
- 16. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14] claim 1 wherein [release of profiles of variable] varying release rates and varying release [duration] durations are achieved by varying a ratio of [blending] uncapped and [capped polymer] end-capped polymers [in different ratios] within the same [microshreres] microcapsules.
- 17. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6 [or 7 or 8 or 9 or 10 or 11 or 13 or 14] wherein the [entrapped] active agent is a polypeptide and said polypeptide is [any of the] a vaccine [agents] agent against enterotoxigenic E. coli (ETEC) [such as CFA/I, CFA/II, CS1,CS3, CS6 and CS17 and other ETEC-related enterotoxins].
- 18. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6 [or 7 or 8 or 9 or 10 or 11 or 13 or 14] wherein the [entrapped] active agent is a polypeptide and said polypeptide [consists of] comprises peptide antigens for immunization against enterotoxigenic E. coli (ETEC) [of] having a molecular weight range of about 800-5000 daltons [for immunization against enterotoxigenic E. coli (ETEC)].

- 19. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5] <u>claim 1</u>, wherein said biologically active [agents are] <u>agent</u> is selected from the group consisting of water-soluble hormone drugs, antibiotics, antitumor agents, anti inflammatory agents, antipyretics, analgesics, antitussives, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer agents, antidepressants, antiallergic drugs, cardiotonics, antiarrhythmic drugs, vasodilators, antihypertensives, diuretics, anticoagulants, and antinarcotics, in the molecular weight range of 100-100,000 daltons.
- 20. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8] claim 1, wherein said biodegradable poly(lactide/glycolide) is in an oil phase, and is present in about 1-50% (w/w).
- 21. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14] claim 1, wherein a concentration of the active agent is in [the] a range of 0.1 to about 60% (w/w).
- 22. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14] claim 1, wherein a ratio of [the] an inner aqueous to oil [phases] phase is about 1/4 to 1/40 (v/v).

Claim 25, line 1, replace "claims 23 or 24" with --- claim 23---.

Claim 26, line 1, replace "claims 23 or 24" with --- claim 23---.

28. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 6, wherein, when the [entrapped] said active agent is a polypeptide and said polypeptide is active at a low pH and is entrapped in said polymers, [such as LHRH, adrenocorticortropic hormone, epidermal growth factor, calcitonin released] said polypeptide is bioactive when released.

29. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 6 or 7 or 8 or 9 or 10 or 11] claim 6, wherein[,] said active agent is a peptide and when [entrapped] the peptide [such as histatin] is entrapped and is inactive at a low pH, a pH-stabilizing agent of inorganic salts [are] is added to [the] an inner aqueous phase during manufacture of said microcapsule to maintain biological activity of the released peptide.

30. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 6 or 7 or 8 or 9 or 10 or 11] claim 6, wherein, when [entrapped] said active agent is a polypeptide, the polypeptide [such as histatin] is inactive at a low pH, a non-ionic surfactant [such as] selected from the group consisting of polyoxyethylene sorbitan fatty acid esters (Yween 80, Tween 60, and Tween 20) and polyoxyethylene — polyoxypropylene block copolymers (Pluronics) is added to [the] an inner aqueous phase during manufacture to maintain biological activity of the released polypeptide.

31. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 29, wherein placebo [spheres] microcapsules loaded with the pH-stabilizing agents are coadministered with the polypeptide-loaded [spheres] microcapsules to maintain [the] a solution pH around the polypeptide-loaded microcapsules and preserve [the] biological

activity of [the] released <u>peptides</u> [peptide in instances where the addition of pH-stabilizing agents in the inner aqueous phase is undesirable for the successful encapsulation of the acid pH sensitive polypeptide].

- 32. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of claim 29, wherein placebo [spheres] microcapsules loaded with non-ionic surfactant are coadministered with polypeptide-loaded microcapsules [spheres] to maintain biological activity of released peptides [peptide where the addition of non-ionic surfactants in the inner aqueous phase is undesirable for successful encapsulation of the acid pH sensitive polypeptide].
- 33. (Amended) The [microcapsules] microcapsule pharmaceutical formulation of [claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 13 or 14] claim 2, wherein [comprising a blend of] said uncapped and [capped] end-capped polymers [polymer, wherein] are present in an amount wherein complete solubilization of the copolymer leaves no residual [polymer] polymers at [the] a site of administration and occurs concurrently with [the] a complete release of the [entrapped] active agent from said microcapsule.
- 34. A process <u>for ameliorating or preventing a disease or disorder in a human or nonhuman animal comprising administering parenterally to said animal a pharmaceutically-effective amount of a microcapsule of claim 1 [of using microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via parenteral routes, such as intramuscular and subcutaneous].</u>

- 35. (Amended) A process for ameliorating or preventing a disease or disorder in a human or nonhuman animal comprising administering topically to said animal a pharmaceutically-effective amount of a microcapsule of claim 1 [of using microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via topical routes].
- 36. (Amended) A process for ameliorating or preventing a disease or disorder in a human or nonhuman animal comprising administering orally to said animal a pharmaceutically-effective amount of a microcapsule of claim 1 [of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via oral routes].
- 37. (Amended) A process for ameliorating or preventing a disease or disorder in a human or nonhuman animal comprising administering nasally, rectally, transdermally or vaginally to said animal a pharmaceutically-effective amount of a microcapsule of claim 1 [of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via nasal, transdermal, rectal, and vaginal routes].

Please add the following claims:

--38. (New) The microcapsule pharmaceutical formulation of claim 17, wherein said enterotoxigenic E. coli is selected from the group consisting of CFA/I, CFA/II, CS1,CS3, CS6 and CS17 and other ETEC-related enterotoxins.

- 39. (New) The microcapsule pharmaceutical formulation of claim 28, wherein said polypeptide is selected from the group consisting of LHRH, adrenocorticortropic hormone, epidermal growth factor and calcitonin.
- 40. (New) The process of claim 34, wherein said administering parenterally comprises administering intramuscularly or subcutaneously.
- 41. (New) A process of maintaining a solution pH around the polypeptide-loaded microcapsule of claim 6, comprising coadministering placebo microcapsules loaded with pH-stabilizing agents with the polypeptide-loaded microcapsules, wherein said placebo microcapsules preserve biological activity of peptides released from said polypeptide loaded microcapsules.
- 42. (New) A process of maintaining biological activity of released peptide comprising coadministering placebo microcapsules loaded with non-ionic surfactant with said microcapsule pharmaceutical formulation of claim 29.
- 43. (New) The microcapsule pharmaceutical formulation of claim 7, wherein said histatin consists of 12 amino acids and has a molecular weight of 1563.
- 44. (New) A controlled release microcapsule pharmaceutical formulation for burst-free sustained, programmable release of biologically active agent over a duration from 1-100 days, comprising an active agent encapsulated within a biodegradable poly(lactide/glycolide) having a lactide/glycolide ratio of 90/10 to 40/60 and the end capped/uncapped form of said poly(lactide/glycolide) in the ratio of 100/0 to 1/99.
- 45. (New) The process of claim 24, wherein a solvent-saturated external aqueous phase is added to emulsify the inner w/o emulsion prior to addition of the external

aqueous layer, to provide microcapsules of narrow size distribution range between 0.05-500µm.

46. (New) The process of claim 24, wherein a low temperature of about 0-4°C is provided during preparation of the inner w/o emulsion, and a low temperature of about 4-20°C is sprovided during preparation of the w/o/w emulsion to provide a stable emulsion and high encapsulation efficiency.--.

## **REMARKS**

An early and favorable action on the merits is respectfully requested.

Claims 1-46 are pending in the application. Claims 1-22, 25, 26 and 28-37 have been amended. Claims 38-46 are newly added. The specification has also been amended to correct various spelling, grammatical and idiomatic errors. No new matter has been added.

The claims have been amended to specifically address the Examiner's comments and section 112 rejections in the office actions of the parent application 08/590,973.

Additionally, the terms "uncapped" and "end-capped" are defined in the specification at page 8, lines 5-18.

The Examiner indicated in the parent application (08/590,973) that claim 38 was allowable. Claim 38 of the parent application (08/590,973) appears in this Preliminary Amendment as new claim 44. Hence, it is believed that new claim 44 would also be allowable.

If the Examiner has any questions, or would like to suggest alternative claim language, he is invited to contact Applicant's representative at (301) 924-9500.

Respectfully submitted,

By

Caroline Nash, Reg. No. 36, 329

for: Charles H. Harris, Reg. No. 34,616

Attorney for Applicants
U.S. Army Medical Research
and Materiel Command

ATTN: MCMR-JA

Fort Detrick, MD 21702-5012

## NOVEL, "BURST-FREE" SUSTAINED RELEASE POLY(LACTIDE/GLYCOLIDE) MICROSPHERES

5

### I. GOVERNMENT INTERESTS

The invention described herein may be manufactured, licensed and used by or for governmental purposes without the payment of any royalties to us thereon.

### II. CROSS REFERENCE

This application is a continuation-in-part of U.S. Patent application Serial No. 08/446,149, filed May 22, 1995.

## III. FIELD OF THE INVENTION

20

This invention relates to providing novel biocompatible and biodegradable microspheres for burst-free programmable sustained release of biologically active agents, inclusive of polypeptides, over a period of up to 100 days in an aqueous physiological environment.

25

25

5

### IV. BACKGROUND OF THE INVENTION

Several publications and patents are available for sustained release of active agents from biodegradable polymers, particularly, poly(lactide/glycolides) (PLGA). Prior usages of PLGA for controlled release of polypeptides have involved the use of molar ratios of lactide/glycolide (L/G) of 75/25 to 100/0 for molecular weights >20,000. Further prior art preparations of PLGA utilized fillers or additives in the inner aqueous layer to improve the stability and encapsulation efficency and/or to increase the viscosity of the aqueous layer, thereby modulating polymer hydrolysis and the biologically active agent or polypeptide release.

In addition, the prior art use of PLGA copolymers were end-capped, in that the terminal carboxyl end groups were blocked. In these end-capped co-polymers, the microcapsule preparations exhibited a low to moderate burst release of ~ 10-40% of the entrapped polypeptide in the first 24 hours after placement in an aqueous physiological environment. In part, these characteristics are due to the use of fillers in the inner aqueous phase.

Further, a 1-month release of polypeptide is known with the use of a 75/25 co-polymer of PLGA of Mw <20,000.

Investigations in controlled release research has been proceeding especially to obtain a 1 to 2 month delivery system

for biologically active agents or polypeptides using poly(lactide/glycolide) polymers. However, most of these systems have one or more of the following problems: Poor encapsulation efficency and large 'burst release' followed by an intermediate 'no release' or 'lag phase' until the polymer degrades. In general, release from these polymers occur over a period from about 4 weeks to about several months. In addition, in order to achieve this release a 50/50 copolymer of MW > 30,000 or a 75/25 copolymer of Mw > 10,000 are employed which often results in residual polymer remaining at the site of administration long after the release of active core.

### V. SUMMARY OF THE INVENTION

This invention provides biocompatible and biodegradable microspheres that have been designed for novel, burst free, programmable sustained release of biologically active agents, including polypeptides over a period of up to 100 days in an aqueous physiological environment.

Unlike currently available release systems, which rely on the use of fillers/additives such as gelatin, albumin, dextran, pectin, polyvinyl pyrrolidone, polyethylene glycol, sugars, etc., and are still prone to low encapsulation efficiencies and "burst effects", this invention achieves high encapsulation and "burst-free" release without the use of any additive. In this invention, burst-free, programmable sustained release is achieved through the use of a unique blend of the 'uncapped' and end-capped forms of poly(lactide/glycolide) polymer in the molecular weight range of 2,000 to 60,000 daltons.

20

25

In general, microspheres described in this invention are produced by a unique emulsification technique wherein an inner water-in-oil (w/o) emulsion is stabilized by dispersing in a solvent-saturated aqueous phase containing an emulsion stabilizer. A ternary w/o/w emulsion is then formed by emulsifying the above w/o emulsions in an external pre-cooled aqueous phase containing an o/w emulsifier. Essentially, the

25

5

inner w/o emulsion is comprised of an aqueous layer containing from ~ 2 to about 20% (w/w) of the active agent to be entrapped and an oil layer containing poly(lactide/glycolide) copolymer in concentrations ranging from ~ 5 to about-- 50% (w/w oil phase). The copolymer includes molecular weight ranging from 2,000 to about 60,000 daltons, with molar composition of lactide/glycolide from 90/10 to 40/60 and a blend of its uncapped and end-capped forms in a ratio of 100/0 to 1/99. Very high encapsulation efficiencies of about 80 to 100% are achieved depending on polymer molecular weight and structural form.

Programmable release of active core over variable durations between 1-100 days is achieved by a judicious selection of process parameters such as polymer concentration, peptide concentration and the aqueous/oil phase ratio.

This invention is particularly suitable for high encapsulation efficiencies and burst-free, continuous programmable release of polypeptides of molecular weights ranging from 1,000 to about 250,000 daltons, and also other biologically active agents over a period of 1-100 days. A uniqueness of the invention is that when using a 100/0 blend of the uncapped and capped polymer, the final phase of active core release is concurrent with the complete solubilization of the polymer to innocuous components, such as lactic and glycolic acids. This is a significant advantage over the currently available 30 day - release systems wherein a major regulatory concern is about toxicity of residual polymer at the site of administration, long

25

5

after release of the active core.

The microcapsules described in this invention are suitable for administration via several routes such as parenteral (intramuscular, subcutaneous), oral, topical, nasal, rectal and vaginal routes.

### VI. BRIEF DESCRIPTION OF DRAWINGS

- FIG. 1 shows a comparison of drug release from a conventional system versus a controlled release system. Peak and valley levels from conventional administrations are shown, in contrast to the steady therapeutic levels from the controlled release administration.
- FIG. 2 shows a scanning electron micrograph of PLGA microspheres prepared by the process described in the invention using 50/50 uncapped polymer of Mw 8-12k dalton and shows superior sphere morphology, sphere integrity, and narrow size distribution.
- FIG. 2a shows a scanning electron micrograph of PLGA microspheres prepared by conventional solvent evaporation method using a 50/50 12k uncapped polymer of Mw 8-12k dalton.
- FIG. 3 shows cumulative Histatin release from PLGA microspheres, wherein release profiles from several batches are prepared using 50/50, uncapped polymer (of Mw 8-12k dalton) and wherein the process parameters are varied to modulate release between 1 and 35 days.
  - FIG. 4 shows a scanning electron micrograph of solid, smooth

25

5

spherical surfaces of PLGA microspheres prepared by the method of in the invention using 50/50, end-capped polymer (of Mw 30-40k dalton).

FIG. 5 shows cumulative Histatin release from PLGA microspheres, wherein the release profiles are from several batches prepared using 50/50, uncapped and end-capped polymer of Mw 30-40k daltons, and wherein the process parameters are varied to modulate release between 28 to 60 days.

FIG. 6 shows cumulative Histatin release from PLGA microspheres, wherein combined release profiles from several batches have been prepared using 50/50, uncapped and end-capped polymer of Mw 8-40k daltons, while varying the process parameters to modulate release between 1 and 60 days.

FIG. 7 shows a cumulative percent release of LHRH from PLGA microspheres prepared using uncapped polymer of Mw 8-12 daltons.

### DETAILED DESCRIPTION OF THE INVENTION

This invention relates to the design of biocompatible and biodegradable microspheres for novel, programmable sustained release of biologically active agents, including polypeptides over a period of up to 100 days in an aqueous physiological environment with little or no burst release.

Unlike currently available release systems which rely on the use of fillers/additives such as gelatin, albumin, dextran, pectin, polyvinyl pyrrolidone, polyethylene glycol, sugars, etc., and are still prone to low encapsulation efficiencies and "burst effects", this invention achieves high encapsulation efficiency

25

5

and 'burst-free' release without the use of any additive. In this invention, burst-free, programmable sustained release is achieved through the use of a unique blend of the 'uncapped' and end-capped forms of poly (lactide/glycolide) polymer.

The 'uncapped' form refers to "poly(lactide/glycolide) with free carboxyl end groups" which renders the polymer more . hydrophilic compared to the routinely used end-capped form. Currently used 'end-capped' polymer hydrates between 4-12 weeks depending on the molecular weight, resulting in an intermediate 'no release' or a 'lag phase'. The uncapped polymer hydrates typically between 5 to 60 days depending on the molecular weight, thus releasing its core continuously without a lag phase. A careful blend of the two forms and appropriate molecular weights and L/G ratios, results in a continuous release between 1 to 100 days. In addition, release within this time is programmable by a judicious selection of process parameters such as polymer concentration, peptide concentration and the aqueous/oil phase ratio.

The coploymer in this invention includes molecular weight ranging from 2,000 to 60,000 daltons, a lactide/glycolide ratio of 90/10 to 40/60 and a blend of the uncapped/capped forms in the ratio of 100/0 to 1/99. The molecular weight of the polypeptide may be in the range of 1000 to 250,000 daltons while that of other biologically active agents may range from 100 to 100,000 daltons.

Microcapsules described in this invention are prepared by a

unique aqueous emulsification techinique which has been developed for use with the uncapped polymer to provide superior sphere morphology, sphere integrity and narrow size distribution. This is accomplished by first preparing an inner water-in-oil (w/o) by mixing the solutions of polymer in an organic solvent such as methylene chloride and the biologically active agent in water. This is followed by stabilization of the w/o emulsion in a solvent-saturated aqueous solution containing an o/w emulsifier such as polyvinyl alcohol. A ternary emulsion is then formed by emulsifying the w/o emulsion in an external aqueous phase containing the same emulsifier as above at concentrations ranging from 0.25 - 1% w/v. Microcapsules are hardened upon solvent removal by evaporation, rinsed to remove residual emulsifier and lyophilized. Low temperature is used both at the time of primary emulsification (w/o emulsion formation) and during the formation of the final w/o/w emulsion to achieve stable emulsion and superior sphere characteristics.

In the context of the invention, a biologically active agent is any water-soluble hormone drugs, antibiotics, antitumor agents, antiinflammatory agents, antipyretics, analgesics, antitussives, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer agents, antidepressants, antiallergic drugs, cardiotonics, antiarrhythmic drugs, vasodilators, antihypertensives, diuretics, anticoagulants, antinarcotics, etc.

20

25

5

More precisely, applicants have discovered a pharmaceutical composition and process with the following itemized features:

- 1. A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a biologically active agent over a duration from 1-100 days, comprising an active agent and a blend of uncapped and end-capped biodegradable poly(lactide/glycolide).
- 2. The pharmaceutical formulation of item 1, wherein the biodegradable poly(lactide/glycolide) is a blend of uncapped and capped forms, in ratios ranging from 100/0 to 1/99.
- 3. The microcapsules of items 1 or 2 wherein the copolymer (lactide to glycolide L/G) ratio for uncapped and endcapped polymer is 52/48 to 48/52.
- 4. The microcapsules of items 1 or 2 wherein the copolymer L/G ratio for uncapped and end-capped polymer is 90/10 to 40/60.
- 5. The microcapsules of items 1 or 2 or 3 or 4 wherein the molecular weight of the copolymer is between 2,000-60,000 daltons.
- 6. The microcapsules of items 1 or 2 or 3 or 4 or 5 wherein the biologically active agent is a peptide or polypeptide.
- 7. The microcapsules of item 6, wherein said polypeptide is histatin consisting of 12 amino acids and having a molecular weight of 1563.
- 8. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 characterized by the capacity to completely release histatin in

25

5

an aqueous physiological environment from 1-35 days with a 100/0 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48, and a molecular weight <15,000.

- 9. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 characterized by the capacity to completely release histatin in an aqueous physiological environment from 18-40 days with a 100/0 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 28,000-40,000.
- 10. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 characterized by the capacity to release up to 90% of the histatin in an aqueous physiological environment from 28-70 days with a 0/100 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 10,000-40,000 daltons.
- 11. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 characterized by the capacity to release up to 80% of histatin in an aqueous physiological environment from 56-100 days with a 0/100 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 75/25 and a molecular weight of < 15,000 daltons.
- 12. The microcapsules of items 7 or 8 or 9 or 10 or 11 having analogs of histatin with chain lengths of from 11-24 amino acids of molecular weights from 1,500-3,000 daltons and characterized by the following structures:
  - 1. D S H A K R H H G Y K R K F H E K H H S H R G Y

25

5

- 2. KRHHGYKRKFHEKHHSHRGYR
- 3. KRHHGYKRKFHEKHHSHR
- 4. RKFHEKHHSHRGYR
- 5. AKRHHGYKRKFH
- 6. \*AKRHHGYKRKFH
- 7. KRHHGYKRKF
- \* D-amino acid
- 13. The microcapsules of items 1 or 2 or 3 or 4 or 5 wherein the biologically active agent is a polypeptide Leutinizing hormone releasing hormone (LHRH) that is a decapeptide of molecular weight 1182 in its acetate form, and having the structure:

## p- E H W S Y G L R P G

- 14. The microcapsule of items 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 having a molecular weight of from 1,000 to 250,000 daltons.
- 15. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 wherein release profiles of variable rates and durations are achieved by blending uncapped and capped microspheres as a cocktail in variable amounts.
- 16. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 wherein release of profiles of variable rates and duration are achieved by blending uncapped and capped polymer in different ratios within the same microshreres.
  - 17. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11

25

5

or 12 or 13 or 14 or 15 or 16 wherein the entrapped polypeptide is any of the vaccine agents against enterotoxigenic E. coli (ETEC) such as CFA/I,CFA/II,CS1,CS3,CS6 and CS17 and other ETEC-related enterotoxins.

- 18. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 wherein the entrapped.

  polypeptide consists of peptide antigens of molecular weight range of about 800-5000 daltons for immunization against enterotoxigenic E. coli (ETEC).
- 19. The microcapsules of items 1 or 2 or 3 or 4 or 5 wherein said biologically active agents are selected from the group consisting of water-soluble hormone drugs, antibiotics, antitumor agents, anti inflammatory agents, antipyretics, analgesics, antitussives, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer agents, antidepressants, antiallergic drugs, cardiotonics, antiarrhythmic drugs, vasodilators, antihypertensives, diuretics, anticoagulants, and antinarcotics, in the molecular weight range of 100-100,000 daltons.
- 20. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 wherein said biodegradable poly(lactide/glycolide) is in an oil phase, and is present in about 1-50% (w/w).
- 21. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 wherein concentration of the active agent is in the range of 0.1 to about 60% (w/w).
  - 22. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or

25

5

8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 wherein a ratio of the inner aqueous to oil phases is about 1/4 to 1/40(v/v).

- 23. A process for preparing controlled release microcapsule formulations characterized by burst-free, sustained, programmable release of biologically active agents comprising: Dissolving biodegradable poly (lactide/glycolide), in uncapped form in methylene chloride, and dissolving a biologically active agent or active core in water; adding the aqueous layer to the polymer solution and emulsifying to provide an inner water-in-oil (w/o) emulsion; stabilizing the w/o emulsion in a solvent-saturated aqueous phase containing a oil-in-water (o/w) emulsifier; adding said w/o emulsion to an external aqueous layer containing oil-in-water emulsifier to form a ternary emulsion; and stirring the resulting water-in-oil-in-water (w/o/w) emulsion for sufficient time to remove said solvent, and rinsing hardened microcapsules with water and lyophilizing said hardened microcapsules.
- 24. A process for preparing controlled release microcapsule formulations characterized by burst-free, sustained, programmable release of biologically active agents comprising:

dissolving biodegradable poly(lactide/glycolide) in endcapped form in methylene chloride, and dissolving a biologically active agent or active core in water; adding the aqueous layer to the polymer solution and emulsifying to provide an inner waterin-oil emulsion; stabilizing the w/o emulsion in a solventsaturated aqueous phase containing a oil-in-water (o/w)

25

5

emulsifier; adding said w/o emulsion to an external aqueous layer containing oil-in-water emulsifier to form a ternary emulsion; and stirring a resulting water-in-oil-water (w/o/w) emulsion for sufficient time to remove said solvent; and rinsing hardened microcapsules with water; and lyophilizing said hardened microcapsules.

- 25. The process of items 23 or 24 wherein a solvent-saturated external aqueous phase is added to emulsify the inner w/o emulsion prior to addition of the external aqueous layer, to provide microcapsules of narrow size distribution range between  $0.05-500\mu m$ .
- 26. The process of items 23 or 24, wherein a low temperature of about 0-4°C is provided during preparation of the inner w/o emulsion, and a low temperature of about 4-20°C is provided during preparation of the w/o/w emulsion to provide a stable emulsion and high encapsulation efficiency.
- 27. The process of items wherein a 100/0 blend of uncapped and end-capped polymer is used to provide release of the active core in a continous and sustained manner without a lag phase.
- 28. The microcapsules of items 6, wherein, when the entrapped polypeptide is active at a low pH, such as LHRH, adrenocorticotropic hormone, epidermal growth factor, calcitonin released polypeptide is bioactive.
- 29. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11, wherein, when entrapped peptide such as histatin is inactive at a low pH, a pH-stabilizing agent of inorganic salts are added to

25

5

the inner aqueous phase to maintain biological activity of the released peptide.

- 30. The microcapsules of items 6 or 7 or 8 or 9 or 10 or 11 wherein, when entrapped polypeptide such as histatin is inactive at a low pH, a non-ionic surfactant such as polyoxyethylene sorbitan fatty acid esters (Tween 80, Tween 60 and Tween 20) and polyoxyethylene polyoxypropylene block copolymers (Pluronics) is added to the inner aqueous phase to maintain biological activity of the released polypeptide.
- 31. The microcapsules of items 29, wherein placebo spheres loaded with the pH-stabilizing agents are coadministered with polypeptide-loaded spheres to maintain the solution pH around the microcapsules and preserve the biological activity of the released peptide in instances where the addition of pH-stabilizing agents in the inner aqueous phase is undesirable for the successful encapsulation of the acid pH sensitive polypeptide.
- 32. The microcapsules of item 30 wherein placebo spheres loaded with non-ionic surfactant are coadministered with polypeptide-loaded spheres to maintain biological activity of the released peptide where the addition of non-ionic surfactants in the inner aqueous phase is undesirable for successful encapsulation of the acid pH sensitive polypeptide.
- 33. The microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 comprising a blend of uncapped and capped polymer, wherein complete

solubilization of the copolymer leaves no residual polymer at the site of administration and occurs concurrently with the complete release of the entrapped agent.

- 34. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 for human administration via parenteral routes, such as intramuscular and subcutaneous.
- 35. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 for human administration via topical route.
- 36. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 for human administration via oral routes.
- 37. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 for human administration via nasal, transdermal, rectal, and vaginal routes.

25

20

25

5

## Conservation of bioactivity of polypeptides

As the polymer degrades rapidly, there is a preciptitous drop in pH accompanied by the release of soluble oligomers in the microenvironment which may affect the biological activity of acid pH-sensitive peptides/proteins. In such instances, biological activity can be maintained by the use of inorganic salts yor buffering agents in the inner aqueous phase codissolved with the peptide.

The following unique advantages are characteristics of this invention:

- 1. Burst-free, prolonged, sustained release of polypeptides and other biocompatible and biodegradable microcapsules up to 100 days in an aqueous physiological environment without the use of additives in the core.
- 2. Release of active core programmable for variable durations over 1-100 days, by using a blend of uncapped and capped polymer of different molecular weights and copolymer ratio, and by manipulating the process parameters.
- 3. Complete release of the active core is concurrent with complete solubilization of the carrier polymer to innocuous components, such as lactic and glycolic acids, especially when using a 100/0 blend of uncapped/capped polymer. This is of tremendous significance, as most biodegradable polymers currently used for 1-30 day delivery, do not degrade completely at the end of the intended release duration, thereby causing serious concern

25


5

of regulatory authorities on the effects of residual polymer at the site of administration.

4. Ease of administration of the microcapsules in various dosage forms via several routes, such as parenteral (intramuscular and sucutaneous), oral, topical, nasal, vaginal, etc.

The hydrophilic homo-and co-polymers based on D,L-lactide and glycolide contains hydrophilic adjusted homo-and co-polymers with free carboxylic end groups, and is characterized by the formula:

Poly(D,L-lactide-co-glycolide) 50:50



 $(c_3H_4o_2)_n(c_2H_2o_2)_m$ 

n:m = 1:1

Wherein Z= Molecular Weight/130; for example Z=92 for Mw 12,000 and 262 for Mw 34,000.

While the molar ratio of the lactide to glycolide may vary, it is most preferred that the lactide to glycolide copolymer ratio be 50:50.

Reference is now made to FIG. 1 which depicts a blood-drug concentration versus time graph that shows conventional drug administration using a series of dosages compared to an ideal controlled release system. Unfortunately, many drugs have a

25

5

therapeutic range, above which they are toxic and below which they are ineffective. Oscillating drug levels that are commonly observed following systemic administration causes alternating periods of ineffectiveness and toxicity. A sustained-release encapsulated biologically active agent or polypeptide preparation, ideally, will maintain the drug in the desired therapeutic range by means of a single dose, as depicted in the THERAPEUTIC RANGE in FIG.1, where the ideal case for controlled release is shown.

In FIG. 2, there is shown a scanning electron micrograph of PLGA microspheres prepared using 50/50 uncapped polymer of Mw 8-12k dalton. The uncapped polymer has solid, smooth spherical surfaces, and is suited to provide a "burst free" release system.

Table I is a summarization of the microsphere process description for preparing a peptide system (Histatin peptide) having a controlled release over the course of from 1 to 100 days.

Release profiles can be modified by a judicious blend of uncapped and capped polymers either in separate microspheres or in the same microspheres. Release from microcapsule formulations 1 through 21 listed in Table 1, occur independently of each other and hence the cumulative release from blends of these formulations are additive. By blending several formulations of uncapped and end-capped microspheres, release curves of any desired duration can be tailored. In addition, based on the release characteristics of uncapped and end-capped polymers,

20

25

blending of the two forms in a single formulation comprising

of the active core thereby providing release curves of any

achieved by the addition of uncapped polymer to end-capped

polymer in amounts as low as 1% up to 100%.

desirable pattern. Manipulation of polymer hydration and

significantly influence the polymer hydration and hence release

degradation resulting in modulation of release of active core is

different ratios of uncapped to capped polymer, would

Table 1- Microcapsule compositions containing Histatin polypeptide

Compositio n#	Polymer	Polymer Description	а	Theoretic al peptide Core Load (%)	Intern al Phase Ratio (w/o)	Emulsificati on Technique
	L/G Ratio & Type	Mol. Wt.(M w x 10³)	Conc in DCM (w/w			
1°	n' 05/05	12	38	5	1:20	æ
2.	n' 05/05	12	18.5	2	1:20	æ
÷.	05/05	34	10	ហ	1:20	æ
4.	05/05	12	38	ហ	1:4	æ

ш	ω	A	ш	α	œ	æ	ω	ш
1:10	1:10	1:10	1:10	1:10	1:10	1:10	1:10	1:10
ro.	5	ъ	ស	ហ	ى د	ß	ß	2.3
7	10	10	10	23.5	10	7	10	7
34	34	34	12	12	12	12	12	12
50/50	50/50	50/50	75/25	75/25	50/50	50/50	05/05 0,0	50/50 , U
ů.	9	7.	œ.	°6	10.	11.	12.	13.

æ	œ	Ф	Œ	В	ш	Д	
1:10	1:10	1:10	1:10	1:10	1:10	1:10	1:10
R	ъ	ហ	ហ	ហ	ហ	ഥ	ĸ
10	10	10	20	40	ស	10	15
12	34	12	12	12	34	34	34
05/05	n' 05/05	05/05	n' 05/05	n' 05/05	n' 05/05	n' 0s/os	50/50 U
14.	15.	16.	17.	18.	19.	20.	21.

# Acronyms:

L/G ratio: Copolymer composition of lactide/glycolide DCM: Methylene Chloride Mw: Molecular weight in daltons A: w/o/w emulsification without an intermediate step for emulsion stabilization B: w/o/w emulsification with an intermediate step for emulsion stabilization U: Uncapped polymer

25

5

While referring to Table 1 in conjunction with FIG. 3, it can be seen that the cumulative Histatin release from PLGA microspheres from several batches prepared using 50/50 and 75/25 uncapped and end-capped, polymer modulates release between 1 to 100 days by varying the process parameters. 1-35 days by uncapped 50/50, 18-56 days by capped 50/50 and 56-100 days by capped 75/25.

In referring to FIG. 4, a view is provided through a scanning electron micrograph of PLGA microspheres designed for a one to two month release system prepared using end-capped polymer of Mw 30-40k daltons.

FIG. 5 depicts the cumulative Histatin release from PLGA microspheres, in which the release profiles are from several batches prepared using 50/50, uncapped and capped polymer, and varying the process parameters to modulate release between 28 to 60 days.

Figure 6 represents cumulative Histatin release from PLGA microspheres --- these combined release profiles are from several batches prepared using 50/50 uncapped and capped polymer, and varying the process parameters to modulate release between 1-60 days.

In the context of the invention, a biologically active agent is any water-soluble antibiotics, antitumor agents, antipyretics analgesics, anti-inflammatory agents, antitussives, expectorants, sedatives, muscle relaxants, anti epileptics, antiulcer agents,

30

35

40

5

anti-depressants, anti-allergic drugs, cardiotonics, antiarrhythmics drugs, vasodilators, antihypertensives, diuretics, anticoagulants, hormone drugs, anti-narcotics, etc.

In general, "burst free" sustained release delivery of biologically active agents from PLGA microshperes is accomplished in the context of this invention using of 90/10 to 40/60 molar ratios, and ratios of uncapped polymer to end-capped polymer of 100/0 to 1/99.

In general, the approaches for designing the biologically active agents encapsulated in the uncapped and combination uncapped/end-capped PLGA microspheres and characteristics of these encapsulants are briefly set forth below as follows:

- 1. Providing PLGA microspheres of surface morphologies using 50/50 uncapped and capped polymers of Mw ~ 8-40K daltons as shown in Figs. 2 and 4.
- 2. Providing in vitro release of a polypeptide, Histatin from PLGA microspheres, as shown in Figs. 3 and 5, using uncapped and capped polymer of Mw  $\sim$  8-40K daltons and molar ratios such as 50/50 and 75/25.

For example, design of a 1-12 week bioactive compound release system is achieved using PLGA with the following specifications:

1. Polymer molecular weight:

-about 2-60K daltons
2. Copolymer molar ratio (L/G):

- 90/10 to 40/60

3. Polymer end groups:

- uncapped and /or end-capped

and combining judiciously within the following parameters:

- 4. Polymer concentration
  - from 5 to 50%
- 5. Inner aqueous to oil phase ratio:
  - 1:5 to 1:20 (V/V)
- 6. Peptide loads:
- from 2 to about 40% (w/w polymer)

and by using the unique aqueous emulsification method described in the invention.

The uniqueness and novelty of invention may generally be summarized in a brief way as follows:

- 1. Use of uncapped poly(lactide/glycolide) to achieve burst-free, continuous, sustained, programmable release of biologically active agents over 1-100 days.
- 2. Use of a unique aqueous emulsification system to achieve superior microsphere characteristics such as uniform sphere morphology and narrow size distribution.
- 3. Burst-free, prolonged, sustained release of polypeptides and other biologically actice agents from biocompatible and biodegradable microcapsules up to 100 days in an aqueous physiological environment without the use of additives in the inner core.
- 4. Release of active core programmable for variable durations over 1-100 days by using a blend of uncapped and capped polymer for different molecular weights and copolymer rations and manipulating the process parameters.
- 5. Complete release of the active core concurrent with complete solubilization of carrier polymer to innocuous components such as lactic and glycolic acids, especially when using a 100/0 blend of uncapped/capped polymer. This is of tremendous significance as most biodegradable polymers currently in use for 1-30 day delivery, do not degrade completely at the end of the intended release duration causing serious concern for regulatory authorities on the effects of residual polymer at the site of administration.
- 6. Ease of administration of the microcapsules in various dosages forms via several routes such as parenteral (intramusclar and subcutaneous), oral, topical, nasal, vaginal, etc.

The following examples are illustrative of, but not limitations upon the microcapsule compositions pertaining to this invention.

### Example\_1

45

50

40

5

10

15

30

Ç.

and the

Ü

₩<u></u>35

Polylactide/glycolide (PLGA) microcapsules are prepared by a unique aqueous emulsification technique which has been developed for use with the uncapped polymer to provide superior sphere morphology, sphere integrity and narrow size distribution (See Figures 1a and 1b). This is accomplished by dissolving the polymer in a chlorinated hydrocarbon solvent such as methylene chloride and dissolving the biologically active agent in water. A

w/o emulsion is then formed by mixing the solutions of polymer and the active agent by sonication, followed by emulsion stabilization in a solvent - saturated aqueous solution containing polyvinyl alcohol. A ternary emulsion is then formed by emulsifying the w/o emulsion in an external, pre-cooled aqueous phase containing polyvinyl alcohol (0.25 - 1% w/v). Microcapsules are hardened upon removal of solvent by evaporation, rinsed to remove any residual emulsifier, and then lyophilized.

10

15

5

Table 1 lists the microcapsule compositions, Nos. 1-21 thus prepared, consisting of a biologically active polypeptide, Histatin (composed of 12 amino acids and a molecular weight of 1563) and blends of uncapped and capped polymer of ratios 100/0 to 1/99, and having a lactide/glycolide ratio of 90/10 to 40/60, and a molecular weight range between 2000 to 60,000 daltons.

93

1

E. Ţ

35

30

# 

# Example 2

Microcapsule compositions are prepared as described in Example 1 wherein the copolymer L/G ratio is 48/52 to 52/48, and the ratio of uncapped/capped polymer is 100/0. The active core is Histatin (Mw 1563), the polymer molecular weight is < 15,000 and the polymer concentrations vary from 7% to ~ 40% w/w. Compositions 1,2,4 12-14 and 16-18 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment, such as phosphate-buffered saline, pH 7.0 maintained at 37 ± 1°C are plotted as cumulative percentage release versus time, and presented in Figure 2.

Burst-free, variable release from 1-35 days is achieved by varying the polymer concentration from 7 to ~ 40% w/w in the oil phase.

40

### Example 3

Microcapsule compositions are prepared as described in Example 2, wherein the aqueous /oil ratio is varied from 1/4 to 1/20 (v/v). Compositions 1,2,4 and 12 are listed in Table 1.

45

Release profiles of the active core from the compositions in an aqueous physiological environment described in Example 2 are plotted as cumulative percentage release versus time, and presented in Figure 2.

50

Burst-free, continuous release from 1-35 days, with different onset and completion times are achieved by selecting different w/o ratios in the inner core.

10

15

₩<u></u>35

40

45

50

### Example 4

Microcapsule compositions are prepared as described in Example 2, wherein the polymer molecular weight is 28,000-40,000 and polymer concentrations vary from 5% to ~ 15% w/w. Compositions 19-21 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2 are plotted as cumulative percentage release versus time and presented in Figure 3.

Burst-free, variable release from 18-40 days is achieved by varying the polymer concentration.

### Example 5

Microcapsule compositions are prepared as described in Example 2, wherein the ratio of uncapped/capped polymer is 1/99 and polymer concentrations vary between 5% to ~ 12% w/w. Compositions 10 and 11 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2, and plotted as cumulative percentage release versus time and presented in Figure 2.

Burst-free, variable release from 28-70 days is achieved by varying the polymer concentration in the oil phase.

### Example 6

Microcapsule compositions are prepared as described in Example 5, wherein polymer molecular weight is 28,000-40,000 and polymer concentrations vary between 5% to ~ 12% w/w. Compositions 5 and 6 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2 and are plotted as cumulative percentage release versus time, and presented in Figure 3.

Burst-free, variable release from 28-70 days is achieved by varying the polymer concentration.

### Example 7

Microcapsule compositions are prepared as described in Example 6, wherein the aqueous/oil ratio varies between 1/5 to

1/25 (v/v). Compositions 3 and 7 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2, and plotted as cumulative percentage release versus time, and presented in Figure 3.

Burst-free, variable release from 28-70 days is achieved by varying the aqueous/oil ratios.

10

15

ā:

171

113

Ţ

ű

35

30

5

### Example 8

Microcapsule compositions are prepared as described in Example 5, wherein the copolymer ratio is 75/25 and polymer concentrations vary between 5% to ~ 25% w/w. Compositions 8 and 9 are listed in Table 1.

Release profiles of the active core from the compositions in an aqueous physiological environment are described in Example 2, and are plotted as cumulative percentage release versus time, and presented in Figure 2.

### Example 9

Microcapsule compositions are described in Example 2, wherein the active core is leutinizing hormone releasing hormone (LHRH, a decapeptide of molecular weight 1182) and the polymer concentration is ~40% w/w. Release profiles of the active core from the composition in an aqueous physiological environment is described in Example 2, and is plotted as cumulative percentage release versus time, and presented in Figure 4.

Burst-free, continuous and complete release is achieved within 35 days, similar to Histatin acetate.

40

45

50

### Example 10

Microcapsule compositions are prepared as described in Example 2, wherein an additive such as sodium salt (carbonate or bicarbonate) is added to the inner aqueous phase at concentrations of 1-10% w/w to maintain the biological activity of the released polypeptide.

Burst-free, variable release from 1-28 days is achieved similar to Examples 2 & 3, and the released polypeptide is biologically active until 30 days, due to the presence of the sodium salt.

### Example 11

Microcapsule compositions are prepared as described in Example 2, wherein an additive such as a nonionic surfactant, polyoxyethylene/polyoxypropylene block copolymer (Pluronics F68 and F127) is added to either the inner oil or the aqueous phase at concentrations from 10-100% w/w, to maintain the biological activity of the released polypeptide.

10

5

Burst-free, continuous release from 1-35 days is achieved similar to Examples 2 & 3, and the released polypeptide is bioactive due to the presence of the surfactant.

15

### Example 12

Cumulative histatin release from the microcapsule compositions described in Examples 1 through 11 and release profiles plotted in Figures 2 and 3 show the burst-free, programmable peptide release for variable duration from 1-100 days. Virtually any pattern of cumulative release is achievable over a 100 day duration by a judicious blending of several compositions, as shown in these figures.

**3**5

Ţ

40

45

50

25

5

### WE CLAIM

1

- 1. A controlled release microcapsule pharmaceutical formulation for burst-free, sustained, programmable release of a biologically active agent over a duration from 1-100 days, comprising an active agent and a blend of uncapped and end-capped biodegradable poly(lactide/glycolide).
- 2. The pharmaceutical formulation of claim 1, wherein the biodegradable poly(lactide/glycolide) is a blend of uncapped and capped forms, in ratios ranging from 100/0 to 1/99.
- 3. The microcapsules of claims 1 or 2 wherein the copolymer (lactide to glycolide L/G) ratio for uncapped and endcapped polymer is 52/48 to 48/52.
- 4. The microcapsules of claims 1 or 2 wherein the copolymer L/G ratio for uncapped and end-capped polymer is 90/10 to 40/60.
- 5. The microcapsules of claim 3 wherein the molecular weight of the copolymer is between 2,000-60,000 daltons.
- 6. The microcapsules of claim 1 wherein the biologically active agent is a peptide or polypeptide.
- 7. The microcapsules of claim 6, wherein said polypeptide is histatin consisting of 12 amino acids and having a molecular weight of 1563.
- 8. The microcapsules of claim 7 characterized by the capacity to completely release histatin in an aqueous physiological environment from 1-35 days with a 100/0 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G

25

5

ratio of 48/52 to 52/48, and a molecular weight <15,000.

- 9. The microcapsules of claim 7 characterized by the capacity to completely release histatin in an aqueous physiological environment from 18-40 days with a 100/0 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 28,000-40,000.
- 10. The microcapsules of claim 7 characterized by the capacity to release up to 90% of the histatin in an aqueous physiological environment from 28-70 days with a 0/100 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 48/52 to 52/48 and a molecular weight range of 10,000-40,000 daltons.
- 11. The microcapsules of claim 7 characterized by the capacity to release up to 80% of histatin in an aqueous physiological environment from 56-100 days with a 0/100 blend of uncapped and end-capped poly(lactide/glycolide) having a L/G ratio of 75/25 and a molecular weight of < 15,000 daltons.
- 12. The microcapsules of claims 7 or 8 or 9 or 10 or 11 having analogs of histatin with chain lengths of from 11-24 amino acids of molecular weights from 1,500-3,000 daltons and characterized by the following structures:
  - 1. DSHAKRHHGYKRKFHEKHHSHRGY
  - 2. KRHHGYKRKFHEKHHSHRGYR
  - 3. KRHHGYKRKFHEKHHSHR
  - 4. RKFHEKHHSHRGYR

25

5

- 5. AKRHHGYKRKFH
- 6. \*AKRHHGYKRKFH
- 7. KRHHGYKRKF
- \* D-amino acid
- 13. The microcapsules of claim 6 wherein the biologically active agent is a polypeptide Leutinizing hormone releasing hormone (LHRH) that is a decapeptide of molecular weight 1182 in its acetate form, and having the structure:

### p-EHWSYGLRPG

- 14. The microcapsule of claim 6 having a molecular weight of from 1,000 to 250,000 daltons.
- 15. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 wherein release profiles of variable rates and durations are achieved by blending uncapped and capped microspheres as a cocktail in variable amounts.
- 16. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 wherein release of profiles of variable rates and duration are achieved by blending uncapped and capped polymer in different ratios within the same microshreres.
- 17. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 wherein the entrapped polypeptide is any of the vaccine agents against enterotoxigenic E. coli (ETEC) such as CFA/I,CFA/II,CS1,CS3,CS6 and CS17 and other ETEC-related enterotoxins.

25

5

- 18. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 13 or 14 wherein the entrapped polypeptide consists of peptide antigens of molecular weight range of about 800-5000 daltons for immunization against enterotoxigenic E. coli (ETEC).
- 19. The microcapsules of claims 1 or 2 or 3 or 4 or 5 wherein said biologically active agents are selected from the group consisting of water-soluble hormone drugs, antibiotics, antitumor agents, anti inflammatory agents, antipyretics, analgesics, antitussives, expectorants, sedatives, muscle relaxants, antiepileptics, antiulcer agents, antidepressants, antiallergic drugs, cardiotonics, antiarrhythmic drugs, vasodilators, antihypertensives, diuretics, anticoagulants, and antinarcotics, in the molecular weight range of 100-100,000 daltons.
- 20. The microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 wherein said biodegradable poly(lactide/glycolide) is in an oil phase, and is present in about 1-50% (W/W).
- 21. The microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 13 or 14 wherein concentration of the active agent is in the range of 0.1 to about 60% (w/w).
- 22. The microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 13 or 14 wherein a ratio of the inner aqueous to oil phases is about 1/4 to 1/40(v/v).
- 23. A process for preparing controlled release microcapsule formulations characterized by burst-free, sustained, programmable release of biologically active agents comprising: Dissolving

biodegradable poly (lactide/glycolide), in uncapped form in methylene chloride, and dissolving a biologically active agent or active core in water; adding the aqueous layer to the polymer solution and emulsifying to provide an inner water-in-oil (w/o) emulsion; stabilizing the w/o emulsion in a solvent-saturated aqueous phase containing a oil-in-water (o/w) emulsifier; adding said w/o emulsion to an external aqueous layer containing oil-in-water emulsifier to form a ternary emulsion; and stirring the resulting water-in-oil-in-water (w/o/w) emulsion for sufficient time to remove said solvent, and rinsing hardened microcapsules with water and lyophilizing said hardened microcapsules.

24. A process for preparing controlled release microcapsule formulations characterized by burst-free, sustained, programmable release of biologically active agents comprising:

dissolving biodegradable poly(lactide/glycolide) in endcapped form in methylene chloride, and dissolving a biologically
active agent or active core in water; adding the aqueous layer to
the polymer solution and emulsifying to provide an inner waterin-oil emulsion; stabilizing the w/o emulsion in a solventsaturated aqueous phase containing a oil-in-water (o/w)
emulsifier; adding said w/o emulsion to an external aqueous layer
containing oil-in-water emulsifier to form a ternary emulsion;
and stirring a resulting water-in-oil-water (w/o/w) emulsion for
sufficient time to remove said solvent; and rinsing hardened
microcapsules with water; and lyophilizing said hardened
microcapsules.

25

5

- 25. The process of claims 23 or 24 wherein a solvent-saturated external aqueous phase is added to emulsify the inner w/o emulsion prior to addition of the external aqueous layer, to provide microcapsules of narrow size distribution range between  $0.05-500\mu m$ .
- 26. The process of claims 23 or 24, wherein a low temperature of about 0-4°C is provided during preparation of the inner w/o emulsion, and a low temperature of about 4-20°C is provided during preparation of the w/o/w emulsion to provide a stable emulsion and high encapsulation efficiency.
- 27. The process of claim 23 wherein a 100/0 blend of uncapped and end-capped polymer is used to provide release of the active core in a continous and sustained manner without a lag phase.
- 28. The microcapsules of claim 6, wherein, when the entrapped polypeptide is active at a low pH, such as LHRH, adrenocorticotropic hormone, epidermal growth factor, calcitonin released polypeptide is bioactive.
- 29. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11, wherein, when entrapped peptide such as histatin is inactive at a low pH, a pH-stabilizing agent of inorganic salts are added to the inner aqueous phase to maintain biological activity of the released peptide.
- 30. The microcapsules of claims 6 or 7 or 8 or 9 or 10 or 11 wherein, when entrapped polypeptide such as histatin is inactive at a low pH, a non-ionic surfactant such as polyoxyethylene

20

25

5

sorbitan fatty acid esters (Tween 80, Tween 60 and Tween 20) and polyoxyethylene - polyoxypropylene block copolymers (Pluronics) is added to the inner aqueous phase to maintain biological activity of the released polypeptide.

- 31. The microcapsules of claim 29, wherein placebo spheres loaded with the pH-stabilizing agents are coadministered with polypeptide-loaded spheres to maintain the solution pH around the microcapsules and preserve the biological activity of the released peptide in instances where the addition of pH-stabilizing agents in the inner aqueous phase is undesirable for the successful encapsulation of the acid pH sensitive polypeptide.
- 32. The microcapsules of claim 30 wherein placebo spheres loaded with non-ionic surfactant are coadministered with polypeptide-loaded spheres to maintain biological activity of the released peptide where the addition of non-ionic surfactants in the inner aqueous phase is undesirable for successful encapsulation of the acid pH sensitive polypeptide.
- 33. The microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 8 or 9 or 10 or 11 or 13 or 14 comprising a blend of uncapped and capped polymer, wherein complete solubilization of the copolymer leaves no residual polymer at the site of administration and occurs concurrently with the complete release of the entrapped agent.
- 34. A process of using microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 13 or 14 for human

administration via parenteral routes, such as intramuscular and subcutaneous.

- 35. A process of using microcapsules of claims 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via topical route.
- 36. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via oral routes.
- 37. A process of using microcapsules of items 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 13 or 14 for human administration via nasal, transdermal, rectal, and vaginal routes.

20

25

### Abstract

Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer as a blend of uncapped (free carboxyl end group) and end-capped forms ranging in ratios from 100/0 to 1/99.




Fig.1




Fig. 2





Figure Za









Fig. 4

ŧ



Fish





	er Of Attorney Or Apation Related To A l		Docket No. Army 111
n Re Application Of: Jeyenthi,	it al.		
Serial No. 68/590,973 Ja	Filing Date	Examiner Harrison, R.	Group Art Unit
nvention: Nevel Berst-Free Sea	tained Release Poly(Lac	tide/Glycolide)	
			•
OT.	THE ASSISTANT COM	MISSIONER FOR PATENT	S;
lease recognize the following as	🛭 Associate Attorne	y Associate Agent	in this application.
Name:	Marless Titus and Ca	reline Nash	
R <b>eg</b> . No.:	35,843 and 36,329, resp	ectively	
Address:	PLEASE CHANGE C ADDRESS TO:	ORRESPONDENCE	
	Nash & Titus, LLC 3415 Brookeville Read Suite 1000 Brookeville, Maryland		
Tel. No.	(301) 924-9500 er (301	924-9600	
I AIR		/	,

Signature of Principal Atternay or Agent of Record Werten F.W. Bellamy, Reg. No. 27, 029 Intellectual Property Law Division

OTJAG, Department of the Army 901 North Stuart Street

Ariington, VA 22203-1837

Registration Number & Address of Principal Anomey or Agent of Record

Deted: 5/6/99

I certify that this document is being deposited on 1/99 with the U.S. Postal Bervice as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Weekington, D.C. 20231.

Signature of Person Melling Correspondence

Typed or Printed Name of Parson Mailing Correspondence

*, *,	DECLARATION FOR PA	TENT APPLICATI	ON X	Docket Nymber (Optional)
As a below named inv		ubbu Jeyanthi, J		Hamont, Phil Friden,
Robert H. Reid,	F. Donald Robers, Charl	es E. McQueen, J	ean A. Jet	terstrom
My residence, post off	ce address and citizenship are as s	ated below next to my n	áme, '	
I believe I am the original	inal, first and sole inventor (if only on	e name is listed below)	or an onginal, f	irst and joint inventor (if plural
names are listed below Novel Burst-	w) of the subject matter which is claim Free Sustained Release P	ned and for which a part oly (Lactide/Glyc	antis sought of olide)	n the invention entitled, the specification of which
Microspheres	less the following box is checked:			
x was filed on $1/$	24/96 as United St	ates Application Number	or PCT Intern	ational Application
Number 08/5	-			(if applicable).
	ave reviewed and understand the cor	itents of the above ident	tied specificati	on, micinaing the claims, as
	ndment referred to aboye. y to disclose information which is ma	terial to patentability as	defined in Tale	37. Code of Federal
Regulations, § 1.56.				•
I hereby daim foreign	priority benefits under Title 35, Unite	d States Code, § 119 of	any foreign.ap	plication(s) for patent or
	sted below and have also identified b		tion for patent	or inventors certificate
	fore that of the application on which p	ououra & craninador		Priority Claimed
Prior Foreign Application	on(s)			Ppority Claimed ☐ Yes ☐ No
(Number)	(County)	(Day/Mont	√Year Fled)	th '182 th 140
		·		Ų-Yeş □ Nọ
(Number)	(County)	(Day/Mont	(Year Filed)	D Yes No
(Number)	(Country)	(Day/Mont	(Year Fdect)	
	efit under Title 35, United States Cod	. 8 430 of nov. United S	tale emiliatio	ale) listed below and incolor
is the subject matter of	f each of the daims of this application	n is not discosed in the t	prior United Sta	ites application in the manner
provided by the first na	ragraph of Title 35, United States Co	de £ 112 ladinavidado	the dimeter die	schse idomation which is
		00.0 112.1 BLX//CW/9-00	s min con m ou	~~50 1110111161 ~11 11.17
ematerial to patentability	as defined in Title 37. Code of Fede	rai Regulations, § 1.56 v	upicy pecsure s a ma pork in ou	wailable between the filing date
material to patentability	and the national or PCT international	ral Regulations, § 1.56 w	hich became a	wailable between the filing date
material to patentability of the prior application	as defined in Title 37, Code of Fede and the national or PCT international	ral Regulations, § 1.56 w filling date of this applica	rhich became a rtion. 	wailable between the filing date
(Application Number)	as defined in Title 37, Code of Federand the national or PCT international (Fing Date)	ral Regulations, § 1.56 w filing date of this applica te)	hich became a rtion. (Status,	rvailable between the filing date
material to patentability of the prior application	as defined in Title 37, Code of Fede and the national or PCT international	ral Regulations, § 1.56 w filing date of this applica te)	hich became a rtion. (Status,	wailable between the filing date
(Application Number)  [Application Number]	as defined in Title 37, Code of Federand the national or PCT international (Fing Date of Federal (Fing Date of	ral Regulations, § 1.56 w filing date of this applica	(Status -	realiable between the filing date  - patented, pending, abandoned)  - patented, pending, abandoned)  ct all business in the
(Application Number)  [Application Number]  [Application Number]  [Application Number]  [Application Number]	vas defined in Title 37, Code of Federand the national or PCT international  (Fing Da  (Fing Da  bowing attorney(s) and/or agent(s) to position connected therewith: Earl 1	ral Regulations, § 1.56 w filing date of this applicate)  prosecute this application. Reichert. Reg	(Szaus -  (Szaus -  n and to transa	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy
(Application Number)  (Application Number)  (Application Number)  Thereby appoint the foll Reg #27,029; Will	(Fing Date of Section of American of Ameri	ral Regulations, § 1.56 w filing date of this application  (b)  prosecute this application  Reichert, Reg  986; Maj Murray	(Status -  (Status -  and to transa #24,331; W B. Baxter	patented pending abandoned)  patented pending abandoned)  ct all business in the lerten F.W. Bellamy  , Reg #33,646
(Application Number)  (Application Number)  (Application Number)  Thereby appoint the following from the fol	was defined in Title 37. Code of Federal and the national or PCT international (Fing Date (Fing Dat	ral Regulations § 1.56 w filing date of this application  (a)  (b)  (c)  (c)  (c)  (d)  (e)  (e)  (e)  (e)  (e)  (e)  (f)  (e)  (f)  (e)  (f)  (f	(Szaus -  (Szaus -  n and to transa	patented pending abandoned)  patented pending abandoned)  ct all business in the lerten F.W. Bellamy  , Reg #33,646
(Application Number)  (Application Number)  (Application Number)  Thereby appoint the foll Reg #27,029; Will	was defined in Title 37. Code of Federal and the national or PCT international (Fing Date of Fing Date of Final Date of Fing Date of Fi	filing date of this application (application)  prosecute this application (application)  Reichert, Reg (application)  Application	(Sztus - (Sztus - n and to transa #24,331; W B. Baxter	patented pending abandoned)  patented pending abandoned)  ct all business in the lerten F.W. Bellamy  , Reg #33,646
(Application Number)  (Application Number)  (Application Number)  Thereby appoint the following from the fol	was defined in Title 37. Code of Federal and the national or PCT international (Fing Date of Fing Polymer of	filing date of this application (and the process of the application)  The prosecute this application (and the process of the p	(Sztus - (Sztus - n and to transa #24,331; W B. Baxter	patented pending abandoned)  patented pending abandoned)  ct all business in the lerten F.W. Bellamy  , Reg #33,646
Application Number)  (Application Number)  (Application Number)  Thereby appoint the following from the foll	was defined in Title 37. Code of Federal and the national or PCT international (Fing Date (Fing Dat	ral Regulations, § 1.56 w filing date of this application of the process of the application of the process of t	(Status -  (Status -  1 and to transa #24,331; W B. Baxter  number	patented pending abandoned)  patented pending abandoned)  ct all business in the lerten F.W. Bellamy  , Reg #33,646
Application Number)  [Application Number]  [	(Fing Da  (Fing	filing date of this application (and the process of this application). Reichert, Reg. 986; Maj Murray  ETY LAW DIVISION E ADVOCATE GENER TREET, SUITE 700, 03-1837	(Sature - Cartier - Cartie	revailable between the filing date  - patented pending abandoned)  - patented pending abandoned)  - ct all business in the  - lerten F.W. Bellamy  - Reg #33,646
(Application Number)	(Fing Da (Fi	filing date of this application (and the process of	(Saturation.  (S	parented pending abandoned)  parented pending abandoned)  ct all business in the lerten F.W. Bellamy  , Reg #33,646   Its made on information and willful false statements and the
(Application Number)	(Fing Da (Fi	ral Regulations, § 1.56 w filing date of this application of the prosecute this application. Reichert, Reg. 986; Maj Murray  at telephone RTY LAW DIVISION E ADVOCATE GENER TREET, SUITE 700, 03-1837  nowledge are true and the winder Section 1001 of The process of the phone of the process of	(Saturation.  (S	parented pending abandoned)  parented pending abandoned)  ct all business in the letter F.W. Bellamy  , Reg #33,646   tts made on information and wilfful false statements and the nited States Code and that
Application Number)  (Application Number)  (	(Fing Da (Fi	ral Regulations, § 1.56 w filing date of this application (management)  prosecute this application (management)  Reichert, Reg (management)  at telephone (management)  E ADVOCATE GENER (TREET, SUITE 700 (management)  TREET, SUITE 700 (management)  The section 1001 of Tapplication or any pater	(Sztus- (Sztus- (Sztus- (Sztus- n and to transa- #24,331; W B. Baxter number. AL. DA  at all statement cwiedge that v it is used thereo	parented pending abandoned)  parented pending abandoned)  ct all business in the letter F.W. Bellamy  , Reg #33,646   tts made on information and wilfful false statements and the nited States Code and that
Address all corresponde  [hereby declare that all belief are believed to be like so made are punish a such willful false statement of first rst inventor application  [hereby declare that all belief are believed to be like so made are punish a such willful false statement of first inventor sign	(Fing Date of Federal And the national or PCT international or PCT international or PCT international (Fing Date of Federal And Office connected therewith: Earl Table of Federal And Office connected therewith: Earl Table of FICE OF THE JUDG OFFICE OFFICE OF THE JUDG OFFICE OFFICE OFFICE OFFICE OF THE JUDG OFFICE OFFI	filing date of this application date of this application.  The prosecute this application. Reichert, Reg., 986; Maj Murray.  The process of t	(Status - (Status - 1 and to transal #24,331; W B. Baxter 1 number.  AL. DA  at all statement (Status - 1 and to transal #24,331; W B. Baxter 1 number.  AL. DA	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy  , Reg #33,646  Its made on information and willful false statements and the nited, States Code and that in.
Application Number)  (Application Number)  (	(Fing Date of Fing Of The Jung Of Fing Of The Jung Of Fing Of The Jung Of North Stuart Sarlington, VA 222 statements made herein of my own known that these statements and further that these statements have sarling of the inventor (given name) family name) that the Final Control of Final Control of Fing Date of Fing	filing date of this application of the polication of the policatio	(Sztra- (Sztra- (Sztra- (Sztra- (Sztra-  (Sztra-	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy  , Reg #33,646  Its made on information and willful false statements and the nited, States Code and that in.
Address all corresponde  [hereby declare that all belief are believed to be like so made are punish a such willful false statement of first rst inventor application  [Application Number]  [Applicati	(Fing Da  (Fing	filing date of this application of the polication of the policatio	(Sztra- (Sztra- (Sztra- (Sztra- (Sztra-  (Sztra-	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy  , Reg #33,646  Its made on information and willful false statements and the nited, States Code and that in.
Application Number)  (Application Number)  (	(Fing Date of Fing Of The Jung Of Fing Of The Jung Of Fing Of The Jung Of North Stuart Sarlington, VA 222 statements made herein of my own known that these statements and further that these statements have sarling of the inventor (given name) family name) that the Final Control of Final Control of Fing Date of Fing	filing date of this application (and the prosecute this application). Reichert, Reg., 986; Maj Murray  at telephone (and the prosecute this application or any patent (and the prosecute this application or any patent (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this application or any patent (and the prosecute this application).	(Sztra- (Sztra- (Sztra- (Sztra- (Sztra-  (Sztra-	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy  , Reg #33,646  Its made on information and willful false statements and the nited, States Code and that in.
Address all corresponde  [hereby declare that all belief are believed to be like so made are punishas such willful false statement of first rst inventor sign Residence 1725 c. Post Office Address _ qoir	(Fing Da (Fi	filing date of this application (and the prosecute this application). Reichert, Reg., 986; Maj Murray  at telephone (and the prosecute this application or any patent (and the prosecute this application or any patent (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this application or any patent (and the prosecute this application).	(Status - (Status - (Status - 1 and to transace #24,331; W B. Baxter 1 number  AL. DA  at all statement (Status - 1 and to transace #24,331; W Catalogue that w  at all statement (Status - 1 and to transace (Status - 1 and to t	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy  , Reg #33,646   ats made on information and wilfful false statements and the nited States Code and that in.
Address all corresponde  [hereby declare that all belief are believed to be like so made are punish such willful false statement of inventor sign Residence 1725 de Post Office Address	(Fing Da (Fi	filing date of this application of the polication of the policatio	(Sztus- (Sztus- (Sztus- (Sztus-  and to transa. #24,331; W B. Baxter number.  AL. DA  at all statement cwiedge that w the 18 of the U t issued thereo thi  Date (  Oth Catizens  Oth Catizens	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy  , Reg #33,646   ats made on information and wilfful false statements and the nited States Code and that in.
Application Number)  (Application Number)  (Application Number)  Thereby appoint the following for and Trademark (Parent and Tradema	(Fing Da (Fi	filing date of this application (and the prosecute this application). Reichert, Reg., 986; Maj Murray  at telephone (and the prosecute this application or any patent (and the prosecute this application or any patent (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this were made with the knurse (and the prosecute this application or any patent (and the prosecute this application).	(Status - (Status - (Status - 1 and to transace #24,331; W B. Baxter 1 number  AL. DA  at all statement (Status - 1 and to transace #24,331; W Catalogue that w  at all statement (Status - 1 and to transace (Status - 1 and to t	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy  , Reg #33,646   ats made on information and wilfful false statements and the nited States Code and that in.
Application Number)  (Application Number)  (Application Number)  (Application Number)  Thereby appoint the following form and Trademark (Reg #27,029; Will Address all correspondent and the solid are belief are belief are belief are punishable and willful false statement of first inventor sign Residence 9725 (Post Office Address — Post Office Address	(Fing Da (Fi	filing date of this application of the polication of the policatio	(Status - (Status - (Status - 1 and to transal #24,331; W B. Baxter 1 number.  AL. DA  at all statement (Status - 1 and to transal #24,331; W B. Baxter 1 number.  AL. DA  at all statement (Status - 1 and to transal #24,331; W B. Baxter  AL. DA  Date  Citizensi	patented pending abandoned)  patented pending abandoned)  ct all business in the letten F.W. Bellamy  , Reg #33,646   ats made on information and wilfful false statements and the nited States Code and that in.

### Docket Number (Optional) DECLARATIO FOR PATENT APPLICATION As a below named inventor, I hereby declare that: Ramasubbu Jeyanthi, John E. an Hamont, Phil Friden, Robert H. Reid, F. Donald Roberts, Charles E. McQueen, Jean A. Setterstrom My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Novel Burst-Free Sustained Release Poly (Lactide/Glycolide) the specification of Microspheres is attached hereto unless the following box is checked: x was filed on 1/24/96 as United States Application Number or PCT International Application Number 08/590,973 and was amended on \_ I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. I hereby daim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Priority Claimed Prior Foreign Application(s) ☐ Yes ☐ No (Day/Month/Year Fied) (County) (Number) ☐ Yes ☐ No (Day/Month/Year Fixed) J (Number) (Country) ☐ Yes ☐ No (Day/Month/Year Fand) (Number) (Country) higher oby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is exterial to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the firing date material to patentability as defined in Title 37, 000000, or application and the national or PCT international filling date of this application. (Status - parented, pending, spandoned) (Application Number) (Fire Date) (Application Number) (Status - parented pending abandoned) (Fing Date) Thereby appoint the following amorney(s) and/or agent(s) to prosecute this application and to transact all business in the Figure and Trademark Office connected therewith: Earl T. Reichert, Reg #24,331; Werten F.W. Bellamy Reg #27,029; William W. Randolph, Reg #28,986; Maj Murray B. Baxter, Reg #33,646 Address all telephone calls to at telephone number INTELLECTUAL PROPERTY LAW DIVISION :Address all correspondence to \_ OFFICE OF THE JUDGE ADVOCATE GENERAL, DA 901 NORTH STUART STREET, SUITE 700 ARLINGTON, VA 22203-1837 I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Table 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Residence 7446 VAN NOY LOOP FORT MERCE MD. 20953 Post Office Address 3444/ 1/4/4 Citizenship USA Fost Office Address 7446 VAN NOY LOOP FORT MEADE, MO. 20755 Full name of secondoint inventor, if any (given name, family name) -\_ Date Citizenship Residence

Additional inventors are being named on separately numbered sheets attached hereto. page 2 of 7

Post Office Address

,`	DE	CLARATION I	OBFAILM	A. I Electrici		والمراهد والماسات والمارة
As	a below named inventor,	, I hereby deck	<sub>nat:</sub> Ramasubbu	Jeyanthi, John	E. mont.	Phil Friden,
Ro Nh	obert H. Reid, F. residence, postoffice ad	Donald Robert Idress and chizens	s, Charles E. hip are as stated b	McQueen, Jean	A. setterst	rom
16	elieve I am the original, fir mes are listed below) of the ovelBurst-Free	rst and sole invento	or (if only one name	is listed below) or a	n original, first an s sought on the i	nd joint inventor (if plu
Mi	icrospheres	Sustained Kel	ease Poly(Lac	tide/Glycolide)	) <u> </u>	ne specification of wh
	attached hereto unless th	e following box is c	:hecked:			
X	was filed on 1/24/96			plication Number of F	CT International	Application
	Number 08/590,97	73 an	d was amended or	1	(	if applicable).
		•				
	ereby state that I have rev			f the above identified	specification, inc	luding the claims, as
	ended by any amendmen			مالم من من المالم من المالم المناسب	ad in Tale 27 Ca	ورزونا فماهم
Rec	xnowledge the duty to dis gulations, § 1.56.	sciose information v	Anich is material in	paternability as defin	ec in the 37, Co	ode of Ledets:
	preby daim foreign priority	, handlike under Till	lo 35 United State	Code 8 119 ef anvi	foreign applicatio	onte i for parent or
inve	entor's certificate listed be ing a filing date before the	cels even bos wol	identified below an	y foreign application f		
	r Foreign Application(s)	,,, <b>,</b> ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,			Priority Claime
					_	Yes No
	(Number)	(Count	y)	(Day/Mont/Yea	: Fied)	D 145 D 160
			·			☐ Yes ☐ No
	(Number)	(Country	у)	(Day/Mont/Yea/	r Filed)	Yes No
123	(Number)	(Count	1	(Day/Mont-Year	· Fáed)	D 143 D 100
2 2			11			
grovi	reby claim the beneficund ne subject matter of each ided by the first paragraphability as defended by the prior application and the	ler Trile 35, United 5 of the claims of this hio! Trile 35, United fined in Trile 37, Co	States Code, § 120 supplication is not of States Code, § 11 de of Federal Regu	of any United States displayed in the prior I 2, I advinowledge the displayers, § 1.56 which	United States app duty to disclose i became available	theaten in the manne Montation which is
Frovi	reby claim the beneficiand no subject mater of each rided by the first paragrapt and to parentability as def	ler Trile 35, United 5 of the claims of this hio! Trile 35, United fined in Trile 37, Co	States Code, § 120 supplication is not of States Code, § 11 de of Federal Regu	of any United States displayed in the prior I 2, I advinowledge the displayers, § 1.56 which	United States app duty to disclose i became available	plication in the manne miormation which is a between the filing d
though the state of the state o	reby claim the beneficiand ne subject matter of each indeed by the first paragraphed at the prior application and the liceton Number	ler Trile 35, United 5 of the claims of this hio! Trile 35, United fined in Trile 37, Co	States Code, § 120 s application is not of States Code, § 11 de et Federal Flego nemational filing da (Fang Date)	of any United States displayed in the prior I 2, I advinowledge the displayers, § 1.56 which	United States applications of the disciple in disciple in the	plication in the manner mormation which is a between the filing d and pending shandoned
Apple	reby claim the beneficiand no subject matter of each ided by the first paragraphed at the prior application and the ication Number;	ler Trile 35, United Sold the claims of this high Trile 35, United timed in Trile 37, Colonational or PCT in	States Code, § 120 supplication is not of States Code, § 11 de of Federal Regulater Englisher da (Fanç Date)	of any United States discissed in the prior leading of the prior leading the state of this application.	United States applications of displacement available (State - patents)	plication in the manner mormation which is a between the filling di and pending shandoned at pending shandoned
LAST ASSESSED IN THE PROPERTY OF THE PROPERTY	reby claim the beneficiand he subject matter of each indeed by the first paragraph and to parentability as defended by prior application and the lication Number) appoint the following appoint the following application to the series of the s	ler Trile 35, United 5 of the claims of this high Trile 35, United 1 need in Trile 37, Co. a national or PCT in externey(s) and/or a	States Code, § 120 sapplication is not of States Code, § 11 de et Federal Regularemational filing da (Fang Date)  (Fang Date)	of any United States discissed in the prior leading of the prior leading the state of this application.	United States applications of displacement available (State - patents)	plication in the manning of the manning of the filling of the fill
the point of the p	reby claim the beneficiand ne subject matter of each rided by the first paragraph and to patentability as defended by application and the lication Number) appoint the following that and Trademark Office of #24,331; Werten F. Murray B. Baxter.	er Trie 35, United Sol the claims of this hol Trie 35, United Inned in Trie 37, Constant of PCT in mational or PCT in efforts.	States Code, § 120 sapplication is not of States Code, § 11 do of Federal Regularemational filling da (Fang Date)  (Fang Date)  gent(s) to prosecut	of any United States displaced in the prior I 2. I advisowledge the states, § 1.58 which he of this application.	United States applications of dray to discisse in became available (States - patents) (States - patents) (States - patents) to transact all but	clication in the manning of the his electron which is electrone the filling of the historian electrone ele
Address Addres	reby claim the beneficiand he subject matter of each rided by the first paragraph and to parentability as defended by application and the cation Number;  action Number;  at and Trademark Office of #24,331; Werten F.  Murray B. Baxter, ass all telephone calls to	ler Trile 35, United 5 of the claims of this high Trile 35, United 1 need in Trile 37, Coanational or PCT in Exercise matterney(s) and/or a sonnected therewith W. Bellamy, Freg #33,646	States Code, § 120 s application is not of States Code, § 11 de et Federal Regularemational filing da (Fang Date)	of any United States discissed in the prior I 2. I acknowledge the stations. § 1.56 which he of this application.  This application and Villiam W. Rand at telephone numbers.	United States applications of the disciple of	clication in the manner minimation which is a between the filling died, pending shandoned winess in the Reichert, 28,986;
Address Addres	reby claim the beneficiand ne subject matter of each rided by the first paragraph and to patentability as defended by application and the lication Number) appoint the following that and Trademark Office of #24,331; Werten F. Murray B. Baxter.	ter Trie 35, United Sol the claims of this hold Trie 35, United Stand in Trie 37, Commented in Trie 37, Commented in Trie 37, Commented in PCT in Expression and the rewith W. Bellamy, Freg #33, 646  INTELLECTUA	States Code, § 120 sapplication is not of States Code, § 11 de of Federal Regularemedional filling da (Fang Date)  (Fang Date)  (Fang Date)  Gent(s) to prosecutive Reg #27,029; The Property Language Code of the Property Code of the Prope	of any United States discissed in the prior I 2. I acknowledge the stations, § 1.56 which he of this application.  This application and William W. Rand at telephone number 100 MINISTON	United States applications of the disciple of	clication in the manner minimation which is a between the filling died, pending shandoned winess in the Reichert, 28,986;
Address Addres	reby claim the beneficiand he subject matter of each rided by the first paragraph and to parentability as defended by application and the cation Number;  action Number;  at and Trademark Office of #24,331; Werten F.  Murray B. Baxter, ass all telephone calls to	er Trie 35, United Sol the claims of this hold Trie 35, United Stand in Trie 37, Coanational or PCT in mational or PCT in matio	States Code, § 120 sapplication is not of States Code, § 11 de et Federal Flegumenational filling da (Fing Date)  (Fing Date)  (Fing Date)  Reg #27,029; U  L PROPERTY LA	of any United States discoved in the prior lead now being the prior lead now being the state of this application and william W. Rand at telephone number of the province of the province of the application and william W. Rand at telephone number of the province of the prior of the	United States applications of the disciple of	clication in the manner minimation which is a between the filling died, pending shandoned winess in the Reichert, 28,986;
Address Addres	reby claim the beneficiand he subject matter of each rided by the first paragraph and to parentability as defended by application and the cation Number;  action Number;  at and Trademark Office of #24,331; Wenten F.  Murray B. Baxter, ass all telephone calls to	er Trie 35, United Sol the claims of this in claims of this in claims of this in claims of the 37, Constant of the claims of the claims of the claims of the country of the claims of the country of the claims of t	States Code, § 120 sapplication is not of States Code, § 11 de of Federal Flegoriemschaftling da  (Fang Date)  (Fang Date)  Gent(s) to prosecut  Reg #27,029; U  L PROPERTY LA  HE JUDGE ADVOTUART STREET.	of any United States discoved in the prior lead now ledge the stations. § 1.56 which the of this application and william W. Rand at telephone number of the stations. § 1.56 which the of this application and william W. Rand Stations of the phone number of the phone n	United States applications of the disciple of	clication in the manning mornation which is a between the filling discharged pending shandoned siness in the Reichert, 28,986;
Addre Addre	reby claim the beneficiand the subject matter of each rided by the first paragraph and to patentability as defended to patentability as defended to application and the scatter Number) appoint the following attand Trademark Office of #24,331; Wenten F. Murray B. Baxter, ass all telephone calls to eas all correspondence to	er Trie 35. United Sol the claims of this in claims of this in claims of this in claims of this in claims of the 37. Consider and in Trie 37. Cons	States Code, § 120 sapplication is not of States Code, § 11 do of Federal Fiegurational filling da  (Fanç Date)  (Fanç Date)  Gent(s) to prosecut  Exeg #27,029; U  L PROPERTY LA  HE JUDGE ADVO  TUART STREET, VA 22203-183	of any United States discissed in the prior I 2. I acknowledge the statens. § 1.56 which he of this application and william W. Rand at telephone number of the prior I in I i	United States appeared by the disciple of the	clication in the manner minimation which is a between the filling discharge standaned discussion in the Reichert, 28,986;
Address Addres	reby claim the beneficiand the subject matter of each rided by the first paragraph and to parentability as defended to parentability as defended to parentability as defended to application and the section Number) appoint the following at and Trademark Office of \$24,331; Wenten F. Murray B. Baxter, ass all telephone calls to eas all correspondence to by declare that all statements.	er Trie 35, United 3 cl the claims of this hiel Trie 35, United 31 united 31 united 37, Co. and an archael or PCT in a consider the rewith W. Bellamy, F. Reg. #33, 646  INTELLECTUAL OFFICE OF TO ARLINGTON, Mants made herein of	States Code, § 120 s application is not of States Code, § 11 de of Federal Fegu- memational filling da  (Fang Date)  (Fang Date)  Gent(s) to prosecut  Reg #27,029; U  L PROPERTY LA  HE JUDGE ADVO  TUART STREET,  VA 22203-183	of any United States discissed in the prior lead now and adjusted the state of this application and william W. Rand at telephone number of the SUITE 700 of the are true and that all are true are true and that all are true ar	United States applications of the disciple of	clication in the manning of the manning which is a between the filing of the pending shandoned siness in the Reichert, 28,986;
the control of the co	reby claim the beneficiand he subject matter of each rided by the first paragraph and to parentability as defended to parentability as defended to parentability as defended to humber) application Number) appoint the following that and Trademark Office of \$24,331; Wenten F. Murray B. Baxter, ass all telephone calls to eass all correspondence to by declare that all stateme are believed to be true; are	er Trie 35. United 3 cl the claims of this in cl Trie 35. United 31 united 31 united 37. Co. and in Trie 33. 646.  INTELLECTUAL OFFICE OF TRIE 301 NORTH ST. ARLINGTON, units made herein claim of further that these	States Code, § 120 sapplication is not of States Code, § 11 de of Federal Fegural memational filling da  (Fang Date) (Fang Date)  Gent(s) to prosecut  Reg #27,029; to  L PROPERTY LA  HE JUDGE ADVO  TUART STREET,  VA 22203-183  Interpretal were in	of any United States discisced in the prior lead now ledge the state of this application. It is application and william W. Rand at telephone number of the General Sulte 700.7	United States applications of the disciple of	clication in the manning minimation which is a between the filing declaration of pending shandoned siness in the Reichert, 28,986;
the solution of the solution o	reby claim the beneficiand ne subject matter of each inded by the first paragraph and to parentability as defended to parentability as defended to parentability as defended to prior application and the season Number) eaton Number eaton Number) eaton Number) eaton Number eaton	er Trie 35. United 3 cl the claims of this hold Trie 35. United timed in Trie 37. Con a national or PCT in material or PCT in material therewith. W. Bellamy, F. Reg. #33.626.  INTELLECTUA OFFICE OF TIME OF THE ARLINGTON, Mants made herein of and further that these fine or imprisonments.	States Code, § 120 sapplication is not of States Code, § 11 de et Federal Fieguriermational filling da (Fing Date)  (Fing Date)  (Fing Date)  L PROPERTY LA HE JUDGE ADVOTUART STREET, VA 22203-183 my own knowledge statements were into or both, under Se	of any United States discisced in the prior lead to the prior lead to the prior lead to the prior lead to the application. It is application and lead to the prior and lead to the prior and lead to the prior to the	United States applications of the United States applications	clication in the manning minimation which is a between the filing declaration of pending shandoned siness in the Reichert, 28,986;
Address with white the second with the second	reby claim the beneficiand no subject matter of each rided by the first paragraphed in the parameter and the prior application and the prior application and the ication Number)  by appoint the following and and Trademark Office of #24,331; Wenten F. Murray B. Baxter, assall telephone calls to eassall correspondence to by declare that all statements are believed to be true; are made are punishable by willful false statements may	er Trie 35. United Sold the claims of this in of Trie 35. United the claims of this in of the 37. Contained in Trie 37. Contained in Trie 37. Contained in Trie 37. Contained or PCT in Standard in PCT in Standard in Trie 1 and 1	States Code, § 120 sapplication is not of application is not of States Code, § 11 do of Federal Flogrammational filling date (Fing Date)  (Fing Date	of any United States discisced in the prior lead to the prior lead to the prior lead to the prior lead to the application. It is application and lead to the application and lead to the prior lead to the application and lead to the prior lead to the lead to t	United States applications of the United States applications	clication in the manner minimation which is a between the filing discovered pending shandoned siness in the Reichert, 28,986;
herei we will no	reby claim the beneficiand ne subject matter of each inded by the first paragraph and to parentability as defended to parentability as defended to parentability as defended to prior application and the season Number) eaton Number eaton Number) eaton Number) eaton Number eaton	er Trie 35. United Sold the claims of this in of Trie 35. United the claims of this in of Trie 35. United the claim of the 37. Constant of the second of the rewith which is a second of the rewith of the second of	States Code, § 120 sapplication is not of application is not of States Code, § 11 do of Federal Flogrammational filling date (Fing Date)  (Fing Date	of any United States discisced in the prior lead to the prior lead to the prior lead to the prior lead to the application. It is application and lead to the application and lead to the prior lead to the application and lead to the prior lead to the lead to t	United States applications of the United States applications of the United States applications.	clication in the manner minimation which is a between the filing discovered pending shandoned siness in the Reichert, 28,986;
Addresses with will not inside	reby claim the beneficiand no subject matter of each inded by the first paragraph and to parentability as defended to parentability as defended to parentability as defended to prior application and the season Number) oby appoint the following that and Trademark Office of \$24,331; Wenten F. Murray B. Baxter. ass all telephone calls to eass all correspondence to by declare that all statements are believed to be true; and made are punishable by willful false statements may ame of third inventor signature ence.	er Trie 35. United Sol the claims of this in of Trie 35. United fund in Trie 37. Constant of the second of the sec	States Code, § 120 sapplication is not of application is not of States Code, § 11 do of Federal Flogrammational filling date (Fing Date)  (Fing Date	c' any United States discisced in the prior lead new force of the prior lead in the application and lead in the prior lead in the prior lead in the le	United States applications of the United States applications of the United States applications.	clication in the manner minimation which is a between the filing discontinuous discont
Addresses with will not inside	reby claim the beneficiand no subject matter of each inded by the first paragraph and to parentability as defended by the first paragraph of prior application and the prior application and the prior application and the first paragraph of the following that and Trademark Office of #24,331; Werten F. Murray B. Baxter. ass all telephone calls to eass all correspondence to by declare that all statements are believed to be true; are made are punishable by willful false statements may ame of third inventor signature ence 22 minutes.	er Trie 35. United 3 of the claims of this in of Trie 35. United the claim of the 37. Con a national or POT in an animal or POT in STELLECTUA.  OFFICE OF TO STATE OF THE STAT	States Code, § 120 sapplication is not of States Code, § 11 de of Federal Flegulational filling da (Firing Date)  (Firing Date	c' any United States discisced in the prior lead new force of the prior lead in the application and lead in the prior lead in the prior lead in the le	United States applications of the United States applications of the United States applications.  United States application of the United States applications of the United States and thereon.	clication in the manner minimation which is a between the filing discontinuous discont
the view of the selection of the selecti	reby claim the beneficiand no subject matter of each index by the first paragraph and to parentability as defended by the first paragraph of prior application and the prior application and the prior application and the first paragraph of the following of and Trademark Office of 124,331; Wenten F. Murray B. Baxter. assall telephone calls to eassall correspondence to by declare that all statements are believed to be true; are made are punishable by willful false statements may ame of third inventor signature ence 22 minutes and 25 minutes and 35 minutes and	er Trie 35. United Sold the claims of this in claims of this in claims of this in claims of this in claims of the 37. Consider and in Trie 37. Consider and in Trie 37. Consider and in Trie and in the second further that these in claims made herein of and further that these in consider and further that the consideration and furthe	States Code, § 120 sapplication is not of States Code, § 11 de of Federal Fiegura (Firing Date)	c' any United States discisced in the prior lead to the prior lead to the prior lead to the prior lead to the application and lead to the application and lead to the phone number of the	United States applications of the United States applications of the United States applications.  United States application of the United States applications of the United States and thereon.	clication in the manner minimation which is a between the filing discontinuous discont
the view of the selection of the selecti	reby claim the beneficiand no subject matter of each inded by the first paragraph and to parentability as defended to parentability as defended to parentability as defended to prior application and the season Number) oby appoint the following that and Trademark Office of \$24,331; Wenten F. Murray B. Baxter. ass all telephone calls to eass all correspondence to by declare that all statements are believed to be true; and made are punishable by willful false statements may ame of third inventor signature ence.	er Trie 35. United Sold the claims of this in claims of this in claims of this in claims of this in claims of the 37. Consider and in Trie 37. Consider and in Trie 37. Consider and in Trie and in the second further that these in claims made herein of and further that these in consider and further that the consideration and furthe	States Code, § 120 sapplication is not of States Code, § 11 de of Federal Fiegura (Firing Date)	c' any United States discisced in the prior lead to the prior lead to the prior lead to the application. It is application and william W. Rand at telephone number of the prior lead to the prio	United States applications of the United States applications of the United States of the reconstruction.	clication in the manner minimation which is a between the filing discovered pending sizandoned siness in the Reichert, 28,986;  Too Information and se statements and the ries Code and that
here will name out to	reby claim the beneficiand no subject matter of each mided by the first paragraphical to parentability as defined prior application and the prior application and the prior application and the prior application and the first paragraphic paragraphic first prior application for the following and and Trademark Office of Murray B. Baxter.  Murray B. Baxter.  Assall telephone calls to pass all correspondence to the pass all correspondence to made are punishable by willful false statements may ame of third inventor signature ence of the paragraphic point inventor.  Mice Address De me point inventor.	er Trie 35. United Sold the claims of this in of Trie 35. United Inned in Trie 37. Constant of the second of the s	States Code, § 120 sapplication is not of States Code, § 11 do of Federal Finguisternational filting da (Fanç Date)  (Fanç	of any United States discisced in the prior lead to the prior lead to the prior lead to the application.  The of this application and william W. Rand at telephone number of the surface of the surface of the application and lead to the prior to the surface of th	United States applications of the United States applications of the United States applications.  United States applications of the United States and thereon.	clication in the manner minimation which is a between the filing discovered, pending sizandoned siness in the Reichert, 28,986;  I on Information and se statements and the state of that
hereit in its ide of the same	reby claim the beneficiand no subject matter of each index by the first paragraph and to parentability as defended by the first paragraph of prior application and the prior application and the prior application and the first paragraph of the following of and Trademark Office of 124,331; Wenten F. Murray B. Baxter. assall telephone calls to eassall correspondence to by declare that all statements are believed to be true; are made are punishable by willful false statements may ame of third inventor signature ence 22 minutes and 25 minutes and 35 minutes and	er Trie 35. United Sold the claims of this in of Trie 35. United the claims of this in of the 37. Contained in Trie 37. Contained in Trie 37. Contained in Trie 37. Contained or PCT in Sold in Trie 1 and 1	States Code, § 120 sapplication is not of States Code, § 11 do of Federal Flogrammational filling date of Federal Flogrammatics of Federal Flogrammatics and the statements were made of the spoke of the application	of any United States discisced in the prior lead to the prior lead to the prior lead to the application.  The of this application and william W. Rand at telephone number of the surface of the surface of the application and lead to the prior to the surface of th	United States applications of the United States applications of the United States of the reconstruction.	clication in the manner minimation which is a between the filing discovered, pending sizandoned siness in the Reichert, 28,986;  I on Information and se statements and the state of that

### DECLARATION FOR PATENT APPLICATION As a below named inventor, I hereby decla at: Ramasubbu Jeyanthi, John E. n Hamont, Robert H. Reid, F. Donald Robers, Charles E. McQueen, Jean A. etterstrom n Hamont, Phil Friden, My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Novel "Burst-Free" Sustained Release Poly (Lactide/Glycolide) the specification of , the specification of which Microspheres is attached hereto unless the following box is checked: as United States Application Number or PCT International Application x was filed on 1/24/96and was amended on \_\_\_\_\_ Number 08/590,973 I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Priority Claimed Prior Foreign Application(s) Yes No (Day/Month/Year Filed) (Country) (Number) Yes No (Day/Month/Year Filed) (Number) (Country) Yes No ū (Day/Montt/Year Feed) (Number) (Country) Ш Thereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner grovided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is meterial to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filling date of the prior application and the national or PCT international filling date of this application. (Status - parented, pending, sciandoned) (Application Number) (Famc Date) (Status - patiented, pending abandoned) (Application Number) (Finc Date) Thereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Fragmand Trademark Office connected therewith: Earl T. Reichert, Reg #24,331; Werten F.W. Bellamy Reg #27,029; William W. Randolph, Reg #28,986; Maj Murray B. Baxter, Reg #33,646 at telephone number \_ Address all telephone calls to Address all correspondence to INTELLECTUAL PROPERTY LAW DIVISION OFFICE OF THE JUDGE ADVOCATE GENERAL. 901 NORTH STUART STREET, SUITE 700 ARLINGTON, VA 22203-1837 I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jecpardize the validity of the application or any patent issued thereon. Full name of fourth inventor (given name, family name). Robert H. Reid Reid Reid Parker Date Residence 48 Lake Side TV. C.V., Fuit Post Office Address Full name of secondoint inventor, if any (given name, family name) -\_ Date \_ Citizenship Residence. Post Office Address Additional inventors are being named on separately numbered sheets attached hereto. page 4 of 7

Dooxat Number (Optional)

### nocket unumber (Obtional) DECLARATION FOR PATENT APPLICATION nat: Ramasubbu Jeyanthi, John E amont, Phil Friden, As a below named inventor, I hereby deck Robert H. Reid, F. Donald Roberts, Charles E. McQueen, Jean A. Setterstrom My residence, post office address and chizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled \_, the specification of which is attached hereto unless the following box is checked: X was filed on 1/24/96 as United States Application Number or PCT International Application 08/590.973 Number and was amended on \_ I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. Lacknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. I hereby daim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's cartificate listed below and have also identified below any foreign application for patent or inventor's cartificate having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s) Priority Claimed Yes No (Day/Montt/Year Fred) (Number) (Country) Yes No (Number) (Country) (Day/Montt/Year Filed) Yes No (Number) (Day/Month/Year Féed) (Country) Thereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar 📚 the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner Provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is meterial to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date the prior application and the national or PCT international filling date of this application. (Application Number) (Status - patented, pending sciandoned) (Fang Date) (Application Number) (Fing Date) (Status - patiented, pending abandoned) Thereby appoint the following amorney(s) and/or agent(s) to prosecute this application and to transact all business in the Francisco Trademark Office connected therewith: Earl T. Reichert, Reg #24,331; Werten F.W. Bellamy, Reg #27,029; William W. Randolph, Reg #28,986; Address all telephone calls to at telephone number Address all correspondence to \_ INTELLECTUAL PROPERTY LAW DIVISION OFFICE OF THE JUDGE ADVOCATE GENERAL. 901 NORTH STUART STREET, SUITE 700 ARLINGTON, VA 22203-1837 I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. F. Donald Roberts Full name of fifth inventor (given name, family name) fifth inventor signature Residence \_\_\_ Reia Chizanship Fost Office Address \_\_\_\_ DOVER MA 02020 Full name of sixth bint inventor, it any (given name, family name) \_ Charles E. McQueen Date Residence\_ Citizenship Post Office Address . X Additional inventors are being named on separately numbered sheets attached hereto. page 5 of 7

My residence, post o	nventor, I hereby declarnat: Ramasubbr , F. Donald Roberts, Charles E office address and citizenship are as stated	below next to my name.	
names are listed belo Novel Burst-	ginal, first and sole inventor (if only one nar ow) of the subject matter which is claimed a Free Sustained Release Poly	me is listed below) or an original, first and j and for which a patent is sought on the inve (Lactide/Glycolide) the	oint inventor (if plural ention entitled specification of which
	nless the following box is checked:		Panalam
x was filed on 1 Number 08/		Application Number or PCT International A on(if a	pplication applicable).
<del></del>			,
	nave reviewed and understand the contents	of the above identified specification, include	ding the claims, as
I acknowledge the du Regulations, § 1.56.	endment referred to above.  ty to disclose information which is material	•	•
I hereby daim foreign inventor's certificate I	n priority benefits under Title 35, United Sta listed below and have also identified below efore that of the application on which priorit	any foreign application for patent or inventor	s) for patent or or's certificate
Prior Foreign Applicat		y b dame.	Priority Claimed
FINI I OLUGI, FUP			☐ Yes ☐ No
(Number)	(Country)	(Day/Month/Year Filed)	Yes No
(Number)	(County)	(Day/Month/Year Filed)	
(Number)	(Country)	(Day/Montt/Year Filed)	Yes No
	nefit under Title 35, United States Code, § 1	• •	Malawand Incofer
	n and the national or PCT international filing	egulations, § 1.56 which became available land date of this application.	between the filing date
		date of this application.	between the filling date
of the prior application	n and the national or PCT international filing	date of this application. (Status - patented	
(Application Number)  (Application Number)  (Application Number)  Thereby appoint the for Patent and Trademark Reg #27,029; Wi	(Fing Date)  (Fing Date)  (Fing Date)  (Fing Date)  (Fing Date)  (Sing Date)  (Fing Date)  (Sing Date)  (Sing Date)  (Sing Date)	(Status - patented  (Status - patented  (Status - patented  scute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg	pending, standoned) , pending, standoned) iness in the F.W. Bellamy #33,646
(Application Number)  (Application Number)  (Application Number)  (I hereby appoint the foreign and Trademark Reg #27,029; Will Address all telephone of the property of the p	(Fing Date)  (Fing Date)  (Fing Date)  (Fing Date)  (Fing Date)  (Solution of the prosection of the pr	(Status - patented  (Status - patented  (Status - patented  cute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg  at telephone number	pending, standoned) , pending, standoned) iness in the F.W. Bellamy #33,646
(Application Number)  (Application Number)  (Application Number)  [Thereby appoint the for Patent and Trademark Reg #27,029; Williams all telephone of the property of the pro	(Fing Date)	(Status - patented (Status - patented (Status - patented scute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg  at telephone number  LAW DIVISION DVOCATE GENERAL, DA	pending, standoned) , pending, standoned) iness in the F.W. Bellamy #33,646
(Application Number)  (Application Number)  (Application Number)  (I hereby appoint the foreign and Trademark Reg #27,029; Will Address all telephone of the property of the p	(Fing Date)	(Status - patented (Status - patented (Status - patented scute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg  at telephone number  LAW DIVISION DVOCATE GENERAL, DA ET, SUITE 700	pending, standoned) , pending, standoned) iness in the F.W. Bellamy #33,646
Application Number)  Application Number)  Thereby appoint the for Patent and Trademark Reg #27,029; Will Address all telephone (calculations)	(Fing Date)	(Status - patented (Status - patented (Status - patented scute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg at telephone number LAW DIVISION DVOCATE GENERAL, DA ET, SUITE 700 1837	pending, scandoned) pending, scandoned) iness in the F.W. Bellamy #33,646
Application Number)  (Application Number)  (Application Number)  Thereby appoint the form and Trademark Reg #27,029; Will Address all telephone of the Address all corresponding the second sec	(Fing Date)	(Status - patented (Status - patented (Status - patented scute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg at telephone number LAW DIVISION DVOCATE GENERAL, DA ET, SUITE 700 1837 edge are true and that all statements made are made with the knowledge that willful false ar Section 1001 of Tatle 18 of the United State	pending, scandoned) pending, scandoned) iness in the F.W. Bellamy #33,646 on information and e statements and the
Application Number)  (Application Number)  (	(Fing Date)  (It is a start of the rewith: Earl T. R. R. It is a start of the rewith: Earl T. R. R. It is a start of the s	(Status - patented  (Statu	pending, scandoned) pending, scandoned) iness in the F.W. Bellamy #33,646 on information and e statements and the
Application Number)  Application Number)  Application Number)  Thereby appoint the formark and Trademark and Trademark and Trademark all telephone and telephone are believed to be like so made are punish such willful false statem.	(Fing Date)  (Office connected therewith: Earl T. R.  (Iliam W. Randolph, Reg #28,98  calls to  INTELLECTUAL PROPERTY  OFFICE OF THE JUDGE AI  901 NORTH STUART STREE  ARLINGTON, VA 22203—  (Il statements made herein of my own knowle true; and further that these statements we hable by fine or imprisonment, or both, under the statements may jecpardize the validity of the application of the statements of the statements of the statements of the statements we hable by fine or imprisonment, or both, under the statements of the statements of the statements we hable by fine or imprisonment, or both, under the statements of the statement of th	(Status - patented  (Statu	pending, scandoned) pending, scandoned) iness in the F.W. Bellamy #33,646 on information and e statements and the
Application Number)  Application Number)  Application Number)  Thereby appoint the form and Trademark Reg #27,029; Wire Address all telephone of Address all corresponding the policy are belief are belief are punish such willful false statem.  Full name of 'sixth Residence /68	(Fing Date)  (Collice connected therewith: Earl T. R.  (Iliam W. Randolph, Reg #28,98)  (Calls to INTELLECTUAL PROPERTY  (OFFICE OF THE JUDGE AI  (OFFICE OF THE JUDG	(Status - patented  (Statu	pending scandoned) pending scandoned) iness in the F.W. Bellamy #33,646 on information and e statements and the
Application Number)  Application Number)  Application Number)  Thereby appoint the form and Trademark Reg #27,029; Winderess all telephone of Address all corresponding the solid are believed to be like so made are punish such willful false statem.  Full name of sixth Residence /66	(Fing Date)  (Office connected therewith: Earl T. R.  (Iliam W. Randolph, Reg #28,98  Calls to INTELLECTUAL PROPERTY  OFFICE OF THE JUDGE AID  901 NORTH STUART STREED  ARLINGTON, VA 22203-1  (Il statements made herein of my own knowledge true; and further that these statements we hable by fine or imprisonment, or both, under the statements made herein of my own knowledge true; and further that these statements we hable by fine or imprisonment, or both, under the statements made herein of my own knowledge true; and further that these statements we hable by fine or imprisonment, or both, under the statement of the application of the statement	(Status - patented (Status - patented (Status - patented coute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg at telephone number LAW DIVISION DVOCATE GENERAL, DA ET, SUITE 700 1837 edge are true and that all statements made are made with the knowledge that willful false ar Section 1001 of Tatle 18 of the United Stat ication or any patent issued thereon.  Chaules Date 10 A Citizenship 4	pending scandoned) pending scandoned) iness in the F.W. Bellamy #33,646 on information and e statements and the
Application Number)  Application Number)  Application Number)  Thereby appoint the form of the part and Trademark Reg #27,029; Wi  Address all telephone of the part and telep	(Fing Date)  (Collice connected therewith: Earl T. R.  (Iliam W. Randolph, Reg #28,98)  (Calls to INTELLECTUAL PROPERTY  (OFFICE OF THE JUDGE AI  (OFFICE OF THE JUDG	(Status - patented (Status - patented (Status - patented coute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg at telephone number LAW DIVISION DVOCATE GENERAL, DA ET, SUITE 700 1837 edge are true and that all statements made are made with the knowledge that willful false are Section 1001 of Tatle 18 of the United Stat ication or any patent issued thereon.  Chaules Date 10 0 Citizenship 4	pending scandoned) pending scandoned) iness in the F.W. Bellamy #33,646 on information and e statements and the
Address all correspond  Thereby declare that all belief are believed to be like so made are punish such willful false statem  Full name of sixth  Fesidence  Full name of secondoi  Residence  Full name of secondoi  Residence	(Fing Date)  (Office connected therewith: Earl T. R.  (Iliam W. Randolph, Reg #28,98  calls to  JOHNELLECTUAL PROPERTY  OFFICE OF THE JUDGE AI  901 NORTH STUART STREE  ARLINGTON, VA 22203—1  (Il statements made herein of my own knowle true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and the tru	(Status - patented (Status - patented (Status - patented coute this application and to transact all bus eithert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg at telephone number LAW DIVISION DVOCATE GENERAL, DA ET, SUITE 700 1837  odge are true and that all statements made are made with the knowledge that willful false ar Section 1001 of Tate 18 of the United Stat ication or any patent issued thereon.  Chaules Date 10 0 Citizenship 4	pending, schandoned) pending, schandoned) iness in the F.W. Bellamy #33,646  on information and e statements and the tes Code and that  M: Que SA
Address all correspond  Thereby declare that all belief are believed to be like so made are punish such willful false statem  Full name of sixth  Fesidence  Full name of secondoi  Residence  Full name of secondoi  Residence	(Fing Date)  (Office connected therewith: Earl T. R.  (Iliam W. Randolph, Reg #28,98  calls to  JOHNELLECTUAL PROPERTY  OFFICE OF THE JUDGE AI  901 NORTH STUART STREET  ARLINGTON, VA 22203—1  (Il statements made herein of my own knowle true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that these statements we hable by fine or imprisonment, or both, under the true; and further that the true; and further that the true; and further that the true;	(Status - patented (Status - patented (Status - patented coute this application and to transact all bus eichert, Reg #24,331; Werten 6; Maj Murray B. Baxter, Reg	pending, scandoned) pending, scandoned) iness in the F.W. Bellamy #33,646  on information and e statements and the tes Code and that  M: Que SA

DECLARATIO" FOR PATENT APPLICATION

Docket Number (Optional)

## DECLARATION FOR PATENT APPLICATION Dooxet Number (Optional)

amont, Phil Friden,

As a below named inventor, I hereby decla nat: Ramasubbu Jeyanthi, John E.

Robert H. Reid, F. Donald Roberts, Charles E. McQueen, Jean A. Setterstrom My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled \_, the specification of which is attached hereto unless the following box is checked: as United States Application Number or PCT International Application x was filed on 1/24/96 and was amended on \_\_\_\_\_ Number 08/590,973 I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Priority Claimed Prior Foreign Application(s) ☐ Yes ☐ No (Day/Montt/Year Fied) (Country) (Number) ☐ Yes ☐ No (Day/Mont/Year Filed) (Country) (Number) ☐ Yes ☐ No (Day/Month/Year Food) (Number) (Country) The reby claim the beneficunder Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar मुं the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner govided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date the prior application and the national or PCT international filing date of this application. (Status - parented, pending, sciandoned). (Fing Date) (Application Number) (Fing Date) (Status - patiented pending abandoned) (Application Number) thereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Earl T. Reicher Reg #24,331; Werten F.W. Bellamy, Reg #27,029; William W. Randolph, Reg #28,986; Earl T. Reichert, Maj Murray B. Baxter, Reg #33,646 at telephone number Address all telephone calls to :Address all correspondence to INTELLECTUAL PROPERTY LAW DIVISION OFFICE OF THE JUDGE ADVOCATE GENERAL. 901 NORTH STUART STREET, SUITE 700 ARLINGTON, VA 22203-1837 I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. Jean A. Setterstrom Full name of seventh inventor (given name, family name) Jean a. Setterstion Date 9 Hay 1996 ~ signatu<u>re</u> 407 Boston Aug Residence \_ Post Office Address \_\_\_\_\_\_ Silver Spring, MO Full name of pint inventor, if any (given name, family name) \_ \_ Date \_ inventor signature Citizenship Residence. Post Office Address . Additional inventors are being named on separately numbered sheets attached hereto. page 7 of 7